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ABSTRACT 
Access to medicines is an essential component of the basic human right to health and a key 
determinant of the importance attached to the health care system of a country. It essentially 
entails the availability and acceptability of the essential medicines on the market and the ability 
of patients to afford such medicines when needed. Globally, countries face access to medicine 
challenges partly because of patents which undoubtedly accounts for excessive pricing of 
medicine. As such, efforts have been made to ensure the accessibility of medicines through the 
Trade-Related Aspects of Intellectual Property Rights (TRIPS) flexibilities of the World Trade 
Organisation (WTO). Beyond these interventions, it is incumbent on Members of the WTO to 
domesticate the flexibilities of the TRIPS Agreement before their utilisation because by their 
very nature, they cannot be self-executed. 
With an estimated population of 29.6 million, about 310 000 people in Ghana are living with 
HIV. The country’s health facilities record 40 per cent of outpatient visits each year and about 
14 550 per 100 000 of the population are infected with tuberculosis with cancer on the rise. 
These diseases require medicines which are mostly patented yet Ghana has access to medicine 
problems despite the existence of a national health insurance system. Ghana has however not 
fully incorporated the TRIPS flexibilities in its national legislations and therefore unable to 
fully utilise the flexibilities as an option to access essential medicines. Questions therefore 
remain as to why and how Ghana can utilise the flexibilities to improve access to medicines.  
Based on an examination of the WTO’s patent system and legislations of Ghana, this mini- 
thesis contends that, the extent of incorporation of the flexibilities are inadequate due to the 
existence of lacunas in the Ghanaian legislations. Furthermore, a comparative assessment with 
South Africa supports an understanding that conditions are not ripe for full utilisation of all the 
flexibilities. It further argues that the utilisation of the TRIPS flexibilities by Ghana has been 
rendered ineffective due to administrative, political, economic and social challenges which 
adversely affects the full utilisation of the flexibilities incorporated and those yet to be 
incorporated. It is therefore important that Ghana adopts a holistic approach taking into 
consideration international best practices if the TRIPS flexibilities must be effectively utilised. 
This mini-thesis concludes that, the TRIPS flexibilities are necessary for accessing essential 
medicines in Ghana to promote the right to health and that a review of Ghana’s current 
legislations to fully incorporate the TRIPS flexibilities and addressing other non-legal 
challenges are the required linchpin for effective utilisation of the TRIPS flexibilities.  
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CHAPTER ONE 
INTRODUCTON 
1.1 Research Background: 
The right to health is a basic human right which is fundamental to the physical and mental 
health of all individuals and aids in the realisation of other basic human rights.1 Recognising 
this right as vital to human existence, countries including Ghana, have commitments at the 
international, regional and national levels to ensure its attainment. At the international level, 
this right is recognised by treaties such as the Universal Declaration for Human Rights 
(UDHR),2 the International Covenant on Civil and Political Rights (ICCPR)3 and the 
International Covenant on Economic, Social and Cultural Rights (ICESCR).4 These treaties 
set out measures which governments must adopt in order to provide good standards of living 
and progressively realise the health needs of their people. At the regional level, the African 
Charter on Humans and Peoples’ Rights (ACHPR)5 recognises the right to health. In addition 
to the ACHPR, the Economic Community of West African States (ECOWAS), of which 
Ghana is a member, admonishes its members to attach importance to this right recognised 
under the Treaty of ECOWAS.6 Ghana, a signatory to the above treaties also imposes an 
obligation on the President, under the Directive Principles of State Policy,7 to report to 
Parliament on the steps taken to realise the basic right to health.8   
A key component of evaluating the basic right to health is, access to medicines. Access to 
medicines refers to the continuous availability and affordability of medicines within the 
shortest possible time.9 This essential component of health is therefore shaped by both supply 
and demand factors such as distributing existing drugs, effectiveness of incentives to develop 
                                                          
1 United Nations Committee on Economic, Social and Cultural Rights, General Comment No. 14: The Right to 
the Highest Attainable Standard of Health 11 August 2000 E/C.12/2000/4 paragraph 1 available at 
https://www.refworld.org/docid/4538838d0.html  (accessed 8 August 2018). 
2Article 25 UDHR (1948) G.A. Res. 217A (III), U.N. Doc. A/810 at 71 available at 
https://www.ohchr.org/EN/UDHR/Documents/UDHR_Translations/eng.pdf (accessed 18 October 2018).  
3 Article 3 ICCPR (1967) 6 ILM 368. 
4 Article 12 ICESCR (1967) 6 ILM 368. 
5 Article 16 ACHPR (1982) 21 ILM 58. 
6 Article 61(2) (d) Treaty of ECOWAS (1993) 35 ILM 660. 
7 The Directive Principles of State Policy urges the entire nation from the President to the citizens to make 
conscious efforts to ensure the realisation of the basic human rights enshrined in the constitution. See 
Constitution of the Republic of Ghana, 1992 chapter 6. 
8 Article 25 Constitution of the Republic of Ghana, 1992. 
9 United Nations Development Group Indicators for Monitoring the Millennium Development Goals (2003) 89. 
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new drugs, income levels, financing and prices.10 Thus to enjoy the basic right to health, 
factors such as receiving appropriate medications, the ability to afford these medications, the 
ability to pay for treatment when needed as well an effective and efficient system to supply 
health needs are essential.  In the case of Minister for Health and others v Treatment Action 
Campaign,11 where the government failed to make  the medicine ‘Nevirapine’ accessible to 
all pregnant women, the Constitutional Court of South Africa held that, the right to health 
entails making provisions to progressively realise this basic right and includes making 
‘Nevirapine’ accessible  to everyone. This case is of persuasive effect to other countries within 
the African sub-region as it imposes an obligation on governments to attach importance to the 
basic right to health and its components.  
Despite it being an essential component of the right to health, access to essential medicines12 
has been a matter of concern as it remains a challenge in most developing countries (DCs), 
including Ghana.13 The people of these countries suffer from diseases such as tuberculosis, 
malaria, human immune deficiency virus/acquired immune deficiency syndrome (HIV/AIDS) 
and other terminal diseases including cardiovascular disease, cancer, diabetes or chronic 
respiratory disease.14 To completely cure or live with these diseases require effective health-
care delivery including medicines which are mostly expensive and may not be covered by 
medical aid. Unfortunately the pharmaceutical industries use patents15 which tend to increase 
the prices of medicines and as such have contributed to access to medicines challenges.16 
                                                          
10 Maskus KE ‘Ensuring Access to Essential Medicines: Some Economic Considerations’ (2001-2002) 20(3) 
Wisconsin International Law Journal 565. 
11 2002 (5) SA 721 para 94 & 95. 
12 Essential medicines are medicines that satisfy the health care needs of the majority of the population. See 
WHO ‘Essential Medicines’ available at   https://www.who.int/topics/essential_medicines/en/ (accessed 15 
October 2018).  
13 Lee J & Hunt P ‘Human Rights Responsibilities of Pharmaceutical Companies in Relation to Access to 
Medicines’ 2012 Journal of Law, Medicine & Ethics 220. 
14 United Nations Sustainable Development Goals Report (2017) available at 
https://unstats.un.org/sdgs/files/report/2017/thesustainabledevelopmentgoalsreport2017.pdf (accessed 29 
August 2018) (hereinafter SDG Report 2017). 
15 A patent is an exclusive right granted for an invention after the technical information of it has been disclosed 
which provides a new way of doing something or offers a new technical solution to a problem. See WIPO 
‘Patents’ available at   http://www.wipo.int/patents/en/ (accessed 29 August 2018).  
16 Saxlin-Hautamaki E ‘Establishing Coherence: The Right to Access to Medicines, Pharmaceutical Patents and 
the WTO Medicines Decision’ 2010 Nordic Journal of Commercial Law 2. 
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The United Nations (UN), recognising the challenges associated with accessing essential 
medicines, places emphasis in its Sustainable Development Goals (SDGs),17 on the need to 
ensure universal access to ‘safe, effective, quality and affordable medicines and vaccines’.18 
Goal number three of the 2017 SDG Report, particularly aims at providing health-care in poor 
countries to reduce child mortality, improve maternal health and fight HIV/AIDS, 
tuberculosis, malaria and other diseases.19 According to the Report, between the year 2000 
and 2015, the global maternal mortality rate declined by 37 per cent and the under-five 
mortality rate declined by 44 per cent. The same period saw a 46 per cent reduction in 
HIV/AIDS, 17 per cent in tuberculosis and 41per cent decrease in incidence of malaria.20 
More HIV positive people are able to live longer due to the increased use of antiretroviral 
drugs and between the year 2000 and 2015, the prevalence of HIV among children under 18 
declined by 72 per cent due to the rapid expansion in access to the aforementioned medicines 
which prevented mother-to-child transfers.21 Undoubtedly, access to medicines from the 
above statistics, has been a key factor contributing to the reduction in the mortality rates of 
various countries. Despite this realisation, access to medicines still remains a problem in most 
countries with its attendant social costs.  
Access to medicines concerns have therefore received much attention worldwide over the 
years and since the year 1995, the multilateral Agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS)22 has been instrumental in addressing intellectual 
property rights (IPRs) issues including those related to patents. The TRIPS Agreement, as part 
of its objectives aims at finding an optimal balance between the right to health on the one 
hand, and the right to protect patentees23 and innovation on the other hand.24 In order to find 
this balance, the Agreement has gone through several phases and has been amended to reflect 
                                                          
17 The Sustainable Development Goals are schemes or guidelines geared towards achieving a better and more 
sustainable future for all by addressing the global challenges relating to social, economic and environmental 
aspect of development. See Szpak A ‘International Solidarity as the Basis for Millennium/Sustainable 
Development Goals’ (2017) 26 Polish Quarterly of International Affairs 120.  
18 SDG Report (2017) 4. 
19 SDG Report (2017) 4. 
20 SDG Report (2017) 4. 
21 SDG Report (2017) 21. 
22 (1994) 33 ILM 1197 as amended (hereinafter TRIPS Agreement). 
23 A person to whom a patent has been granted; who appears on the official government registry as the patent 
owner See Duhaime's Law Dictionary available at http://www.duhaime.org/LegalDictionary/P/Patentee.aspx 
(accessed 16 August 2018). 
24World Intellectual Property Organization (WIPO) ‘Public health and Patents’ available at 
http://www.wipo.int/patent-law/en/developments/publichealth.html  (accessed 16 August 2018).  
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the competing interests so as to improve access to medicines challenges which countries may 
face.  
As a result of complaints to medicine access issues, such as the excessive pricing of essential 
medicines, flexibilities including compulsory license and parallel importation were included 
in the TRIPS Agreement as safeguards pursuant to which Members of the World Trade 
Organisation (WTO) (hereinafter Members), can employ to improve their access challenges. 
The use of these flexibilities is however not a carte blanche but subject to Members 
incorporating or domesticating the flexibilities in their national legislations before their 
utilisation can be triggered.25 This requirement is in accordance with the single undertaken26 
practice of the WTO which makes it mandatory for its Members to incorporate the IPRs rules 
into their national legislations with some special and differential treatment for DCs and least-
developed countries (LDCs).27 Thus Members are given the opportunity to legislate in a 
manner which aids in accessing affordable essential medicines while complying with the 
TRIPS Agreement and fostering innovation. Notwithstanding the deference of the 
implementation of the TRIPS Agreement to Member states, disparities in resources, however, 
places limitations on how the TRIPS flexibilities can be utilised by DCs and LDCs.28 
Owing to the disparities in resources, the WTO adopted the joint Declaration on the 
Agreement on TRIPS and Public Health (Doha Declaration)29 on 14 November 2001 at a 
Ministerial Conference in Doha. This was due to complaints by DCs that developed countries 
were using narrow approaches to interpreting the TRIPS Agreement. To resolve this, the 
Declaration affirmed the right of Members to interpret and implement the Agreement to 
protect public health and in particular, access to medicines.30 Although the Declaration broke 
                                                          
25 Article 1(1) TRIPS Agreement. 
26 By this concept virtually every item agreed as part of the WTO negotiation is part of a whole and indivisible 
package and cannot be agreed separately and for that reason all countries are bound by it. See Wolfe R ‘The 
WTO Single Undertaking as Negotiating Technique and Constitutive Metaphor’ (2009) 12(4) Journal of 
International Economic Law available at https://academic-oup-
com.ezproxy.uwc.ac.za/jiel/article/12/4/835/2193545 (accessed 13 October 2018). 
27 Article 65 TRIPS Agreement. 
28 Musungu SF The Right to Health in the Global Economy: Reading Human Rights Obligations in to the Patent 
Regime of the WTO - TRIPS Agreement (unpublished LLM thesis, Makerere University, 2001) 10 available at 
https://repository.up.ac.za/bitstream/handle/2263/931/musungu_sf_1.pdf;sequence=1 (accessed 5 August 
2018). 
29 WTO Ministerial Declaration of 14 November 2001 WTO Doc. WT/MIN (01)/DEC/1 (2002) 41 ILM 746 
available at https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm 
 (accessed 16 July 2018) (hereinafter Doha Declaration).  
30 Paragraph 4 Doha Declaration. 
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new grounds in guaranteeing access to medicines, it did not resolve all the challenges allied 
with public health.31 This led to further debates to address the major health problems facing 
DCs and LDCs such as insufficient manufacturing capacities. The Ministerial Council was 
therefore charged with finding a solution to the challenges of countries with insufficient 
manufacturing capacities or no manufacturing capacities at all before the end of 2002.32 
On 30 August 2003 a temporal decision was reached to enable countries with production 
capacities to export to LDCs and for countries to import subject to certain conditions 
especially for DCs.33 A permanent amendment was subsequently made in 2005  to implement 
the August 2003 Decision (2005 Amendment).34 The 2005 Amendment however entered into 
force on 23 January 2017 after two-thirds of Members deposited their instruments of 
ratification, paving the way for the export and import of medicines to countries unable to 
manufacture them as well as those with insufficient manufacturing capacities. Members yet 
to sign the Amendment have up to December 2019 to do so, and as such, the August 2003 
Decision can still be invoked to export or import patented medicines.35 
It is obvious that countries including Ghana have numerous right-to-health obligations at the 
national, regional and international levels to ensure the right to health, thereby justifying the 
utilisation of the TRIPS Agreement flexibilities as an option to improve access to medicines. 
The patent system undoubtedly has advanced innovativeness and resulted in the development 
of essential medicines for treatment of emerging diseases through research and development. 
The WTO patent system, despite existing challenges strives to find a balance between the 
patentees and users through its flexibilities in the TRIPS Agreement. Unfortunately, despite 
the reduction of incidents pertaining to the availability of medications, the rate of new 
infection remains high, with emerging diseases and outbreaks, which require essential 
medicines, on the rise.  
The full enjoyment of the right to health still remains a problem as many DCs do not meet the 
requirements for using the flexibilities. As such, the flexibilities cannot be utilised without 
                                                          
31 Hoen E ‘TRIPS, Pharmaceutical Patents, and Access to Essential Medicines: A Long Way from Seattle to 
Doha’ (2002) 3(1) Chicago Journal of International Law 28.  
32 Paragraph 6 Doha Declaration. 
33 WTO Decision of the General Council of 30 August 2003 WT/L/540 available at 
https://www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm  (accessed 17 July 2018).   
34 WTO Protocol Amending the TRIPS Agreement WT/L/641 available at 
https://www.wto.org/english/tratop_e/trips_e/wtl641_e.htm (accessed 17 July 2018).  
35WTO ‘How to accept the Protocol Amending the TRIPS Agreement’ available at 
https://www.wto.org/english/tratop_e/trips_e/accept_e.htm (accessed 16 June 2018).   
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facing challenges from patentees. Members of the WTO which have legislated the flexibilities 
also do not utilise them and questions remains as to why this is so. This may serve as a 
disincentive for countries yet to legislate and apply such legislation to actually do so.  
1.2 Problem Statement  
Ghana is a country located in the western part of Africa with a population estimated at 29.6 
million people.36 As a DC,37 it has been a member of the WTO since 1 January 1995 and a 
member of the General Agreement on Trade and Tariffs (GATT) since 17 October 1957.38 
By virtue of the single undertaken practice of the WTO, Ghana has obligations to use the 
TRIPS flexibilities to address its public health needs. 
The last three decades (1990-present) have however witnessed unprecedented sufferings and 
deaths as a result of diseases such as tuberculosis, malaria and HIV/AIDS in Ghana with 
terminal diseases such as cancer on the rise. An estimated 310 000 (260 000 - 370 000) people 
in Ghana are living with HIV.39 With the whole population susceptible to malaria, this 
endemic disease accounts for 40 per cent of outpatient visits in the country’s health facilities.40 
In the year 2017, 14 550 per 100 000 population of tuberculosis infection were detected by 
Ghana’s health facilities.41 Even though there have been a significant improvement in 
healthcare over the years, Ghana still faces challenges of high mortality rate with low access 
to essential patented medicines contributing to these bottlenecks.42 
                                                          
36 Citifmonline Ghana ‘Ghana’s population hits 29.6m – Statistical Service’ 
http://citifmonline.com/2018/03/12/ghanas-population-hits-29-6m-statistical-service/  (accessed 16 June 2018). 
37 Following the discovery and subsequent exploration of petroleum oil, ‘Ghana experienced impressive 
economic growth and social development which succeeded in halving the level of extreme poverty and placing 
Ghana in the group of medium income developing countries’. See WTO ‘Trade Policy Review: Ghana’ available 
at https://www.wto.org/english/tratop_e/tpr_e/tp398_crc_e.htm (assessed 16 June 2018). 
38 WTO ‘Ghana and the WTO’ available at https://www.wto.org/english/thewto_e/countries_e/ghana_e.htm 
(accessed 28 June 2018). 
39 UNAIDS ‘Country Fact Sheet 2017’ available at http://www.unaids.org/en/regionscountries/countries/ghana 
(accessed 28 June 2018). 
40 Ameme DK, Afari EA & Nyarko KM et al ‘Direct observation of outpatient management of malaria in a rural 
Ghanaian district’ (2014) Pan Afr Medical Journal 1 available at 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407949/ (accessed 28 June 18). 
41 WHO ‘Tuberculosis country profile Ghana’ available at 
https://extranet.who.int/sree/Reports?op=Replet&name=/WHO_HQ_Reports/G2/PROD/EXT/TBCountryProfi
le&ISO2=GH&outtype=pdf (accessed 28 June 18). 
42Cohen JC, Gyansa-Lutterodt M & Torpey K et al ‘TRIPS, the Doha Declaration and increasing access to 
medicines: policy options for Ghana’ (2005) 1:17 Globalization and Health available at 
https://doi.org/10.1186/1744-8603-1-17 (accessed 28 June 18). 
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Ghana’s pharmaceutical policy, therefore aims at ensuring that, there are high quality 
medicines on the market, that there is in existence an efficient supply chain and that there is 
rational use of medicines by professionals and patients.43 For this reason, pharmaceuticals are 
available in many health facilities across the country, however, access is largely limited.  
The role of adequate legislation in resolving challenges such as access to medicines cannot 
be underestimated, especially with the WTO’s patent regime, which provides an option to 
access patented medicines through its flexibilities. The burden, to some extent now lies with 
Ghana to ensure that adequate legislations incorporating the flexibilities are put in place. This, 
however, seems not to be the case as less impact has been made at the national level because 
of challenges including limitation on domestic legislations and other challenges such as 
TRIPS-plus provisions.44 Thus the limitations of domestic legislations and other challenges 
such as infrastructural capacities have contributed to most DCs including Ghana either not 
utilising the flexibilities allowed by the TRIPS Agreement or partially utilising them.45  
Ghana, as part of its efforts to improve access to essential patented medicines and recognising 
the role of law in this, amended its patents legislation in 2003 to incorporate some flexibilities 
such as compulsory license and parallel importation.46 This notwithstanding, other 
flexibilities such as the bolar exception are yet to be incorporated. Thus Ghana is not eligible 
to fully tap into these flexibilities as a means of solving its access to medicines challenges. 
Ghana has also not signed the Protocol amending the TRIPS Agreement though it has only 
up to the year 2019 to do so.  
From the above, it can be argued that, the complaints of patents as a barrier to improving 
access to medicines, to some extent, has been resolved by the international patent regime 
through the flexibilities provided. The incorporation of these flexibilities into the legislative 
framework of Ghana has only been partially done which may have short-changed the options 
that could be explored by the country to improve its access to medicines challenges. 
                                                          
43 Seiter A & Martha Gyansa-Lutterodt M ‘Policy Note: The Pharmaceutical Sector in Ghana’ (2009) 2 available 
at https://www.researchgate.net/publication/242688773_Policy_Note_The_Pharmaceutical_Sector_in_Ghana 
(accessed 28 June 2018). 
44 Baker B ‘Processes and issues for improving access to medicines: Willingness and ability to utilise TRIPS 
flexibilities in non-producing countries’ (2004) 19 available at   
https://www.iprsonline.org/resources/docs/Baker_TRIPS_Flex.pdf (accessed 2 July 2018). 
45 Correa CM ‘Implication of the Doha Declaration on the TRIPS Agreement and Public Health’ (2002) 12 
Health Economic and Drugs EDM 18 available at http://apps.who.int/medicinedocs/pdf/s2301e/s2301e.pdf 
(accessed 2 July 2012). 
46 Patents Act 657 of 2003.    
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Furthermore, the flexibilities incorporated into the legislations are impeded by challenges 
which hinder their effective utilisation. Ghana, therefore, denies itself the opportunity to use 
the flexibilities as an option to help address its access to medicines challenges. The result is 
that, the same channels will be relied on to access medicines and mortality rates may remain 
the same.    
1.3 Research questions  
The main research question to be answered against the background and problem statement set 
out above is: how can Ghana effectively utilise the TRIPS flexibilities to help improve access 
to essential patented medicines?  
In addressing the main research question, the following sub questions will be answered: 
1.1.1 What are the flexibilities provided under the WTO’s patent regime which can be 
used to improve access to essential patented medicines?  
1.1.2 What are the current national legislative frameworks put in place by Ghana to 
help utilise the flexibilities and what is the extent of incorporation and utilisation 
of these flexibilities by Ghana in comparison with that of South Africa? 
1.1.3 What challenges does Ghana face in utilising the flexibilities incorporated in its 
current national legislations and what challenges does it face in incorporating 
other flexibilities provided by the TRIPS Agreement?  
1.1.4 What recommendations can be made to ensure that Ghana fully utilise the 
TRIPS flexibilities to improve access to medicines? 
1.4 Significance of the Research 
Once there is life, human beings will always be susceptible to diseases which will require 
access to medicines for cure or sustenance. The issue of access to medicines, therefore should 
be of much importance to Ghana. As was succinctly put by Nnamuchi:  
‘to contend that an individual possesses the right to life in the absence of the ingredients 
necessary for its sustenance (such as health care) is, on many levels, vacuous. Enjoyment 
of the right to health is not only vital to all aspects of a person's life and well-being, it is 
also crucial to the actualization of all the other fundamental rights and freedoms.’47  
                                                          
47 Nnamuchi O ‘Kleptocracy and Its Many Faces: The Challenges of Justiciability of the Right to Health 
Care in Nigeria’ 2008 Journal of African Law 10. 
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As such, placing priority on the mechanisms for facilitating access to medicines to improve 
health can help improve the productive capacity of countries including Ghana as mortality 
rates will be reduced.48  
This research is also significant in the sense that, as by examining the WTO’s patent regime, 
it will enlighten Ghana’s authorities and pharmaceutical industries about the options available 
to them in terms of mitigating the access to medicine challenges the country faces. This will 
help Ghana comply with its international obligations within the WTO to avoid any protracted 
legal battles in utilising the flexibilities. Examining the flexibilities will thus provide an 
understanding of which flexibility can be best utilised and at what point in time with the 
necessary justifications and the medicines that are involved. This is particularly important as 
there has been a general misconception which seems to suggest that the flexibilities are only 
for certain patented medicines and diseases.49  
A focus on and examination of the current legislative framework of Ghana and that of South 
Africa will help determine whether the extent of incorporation of the TRIPS flexibilities is 
adequate. Considering the role that laws play in addressing challenges in a country, an 
examination of the legislations will help unravel the limitations, gaps and implications with 
respect to the flexibilities that are yet to be domesticated. This will help inform appropriate 
reforms in the future. Though addressing the gaps and implementing the laws does not 
absolutely solve the problem, they are stepping stones toward facilitating access to help 
reduce mortality rates. Additionally, the identification of challenges which goes beyond the 
legal gaps and impede the utilisation of the flexibilities will help to improve access to 
medicines. 
Lastly, this research hopes to influence stakeholders on effectively finding ways of increasing 
access to essential medicines by the use of the TRIPS flexibilities as options to promote the 
right to health in Ghana by the recommendations which will be made following the discovery 
of the existing legal gaps coupled with the challenges that we now face.  
1.5 Methodology 
The research questions have been answered through a desktop-based research conducted 
mainly through a review of the available literature related to the topic. The internet was of 
                                                          
48 Sen A Development as Freedom (1999) 3. 
49 Outterson K ‘Should Access to Medicines and TRIPS Flexibilities Be Limited to Specific Diseases?’ 2008 
American Journal of Law & medicine 280-1. 
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much use as a source, especially websites of international organisations for purposes of 
accurate statistics that were necessary for this research. 
 
Both primary and secondary sources, therefore were used. Primary resources included legal 
instruments, such as international legal instruments that speak to patents and access to 
medicine especially the TRIPS Agreement. A comparative analysis was done between Ghana 
and South Africa on the extent of incorporation of the flexibilities and therefore, the domestic 
legislations of both countries were resorted to. South Africa was selected for this research 
considering the fact that it has been the pacesetter concerning access to medicines in Africa 
exposing the treachery of pharmaceutical industries. The judicial decisions of some countries 
and cases of the WTO were also used. Secondary sources included books, journal articles, 
papers, reports and other scholarly materials relating to the TRIPS Agreement and access to 
medicine particularly in the context of DCs. 
 
The reliance on primary and secondary sources was informed by the nature of the research 
and the vast literature available in relation to the research topic. 
1.6 Chapter outline 
The research is divided into five chapters with each chapter focusing on a specific portion of 
the research topic. 
Chapter One 
Chapter one introduces the research with a discussion of the background and the research 
problem. It further formulates research questions needed to answer the problem statement. 
The significance of the research and methodology adopted for this research are also discussed. 
  
Chapter Two 
This chapter examines the WTO’s patent regime and access to medicines. It further discusses 
the historical antecedents to the TRIPS Agreement, the TRIPS Agreement and its key 
principles as well as an analysis of patents and access to medicines. The chapter identifies and 
examines the flexibilities under the TRIPS Agreement which seek to promote access to 
medicines. 
 
Chapter Three 
Chapter three examines Ghana’s current legislative framework for patent protection and the 
extent of incorporation of the TRIPS flexibilities in the legislations in comparison with that 
of South Africa. This unravels whether or not conditions are ripe for the effective utilisation 
of the flexibilities in Ghana. 
https://etd.uwc.ac.za
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Chapter Four 
This chapter focuses on the challenges faced by Ghana in utilising the WTO flexibilities 
already incorporated into its legislation and the reasons and challenges in incorporating the 
others and utilising them. Also discussed are the possible reasons and implications, for Ghana, 
of not signing and ratifying the TRIPS Amendment. 
 
Chapter Five 
This chapter concludes the research and makes recommendations based on the findings of the 
research.  
https://etd.uwc.ac.za
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CHAPTER TWO 
THE WORLD TRADE ORGANISATION’S PATENT REGIME AND ACCESS TO 
MEDICINES 
 
2.1 Introduction 
Patent protection has become the spotlight of conflict between the ‘private interests and profit 
motives of pharmaceutical companies’ and ‘public health and social impact concerns of 
governments’.50 Some argue51 that patents foster innovation because, if considerable 
resources are spent on inventing new medicines without reimbursement, patentees will not be 
motivated to innovate.52 Others counter that, pharmaceuticals use patents to protect minor 
improvement which impedes access to medicines with much public funds accruing to their 
benefit.53 Be that as it may, the World Trade Organisation's (WTO’s) Agreement on Trade-
Related Aspects of Intellectual Property Rights (TRIPS)54 is a global nexus for medicine 
access issues and aims at balancing these competing interest for sustainable development.55 
This chapter therefore examines the WTO’s patent regime and access to medicines. It focuses 
on the historical antecedents to the TRIPS Agreement, its key principles and the relationship 
between access to medicines and intellectual property rights (IPRs). Also to be examined are 
the flexibilities in the TRIPS Agreement which seek to promote access to medicines, their 
legal basis as well as their conditions for utilisation. This is aimed at answering the question, 
‘What are the flexibilities provided under the WTO’s patent regime which can be used to 
improve access to essential patented medicines?’56  
2.2 The Trade-Related Aspects of Intellectual Property Agreement 
The TRIPS Agreement is the main international legal instrument currently governing IPRs 
under which patents fall. In discussing the patent regime of the WTO, it is important 
                                                          
50 Opati LM  ‘Intellectual property rights in health-Impact on access to drugs’ in Wekesa M and Sihanya B (eds) 
Intellectual property rights in Kenya (2009) 13- 38 21.  
51 Opati LM in Wekesa M and Sihanya B (2009) 21. 
52Trebilcock MJ ‘Economic Analysis of Law’ in Devlin RF (ed) Canadian Perspectives on Legal Theory 
(1991) 111. 
53 Opati LM in Wekesa M and Sihanya B (2009) 22. 
54 (1994) 33 ILM 1197 (hereinafter TRIPS Agreement). 
55 Outterson K ‘Pharmaceutical Arbitrage: Balancing Access and Innovation in International Prescription Drug 
Markets’ (2005) 5 Yale Journal of Health Policy Law and Ethics 193. 
56 See Section 1.3 above. 
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understand the historical antecedents of the TRIPS Agreement, its key principles and features 
and how far the Agreement has come to support access to medicines issues. 
2.2.1 The historical antecedents  
The development of a system for IPRs protection dates back to the 19th century following the 
surge in globalisation leading to the emergence of bilateral and multilateral treaties.57 This 
period saw the emergence of treaties, notable among them, the Paris Convention for the 
Protection of Industrial Property58 and the Berne Convention for the Protection of Literacy 
and Artistic Works.59 The Paris convention in its article 2(1) defines its scope to apply among 
others, to inventions, trademarks and industrial designs.60 The Berne Convention on the other 
hand, deals with copyright protection.61 The United International Bureau for the Protection of 
Intellectual Property (BIRPI) was subsequently created to administer the aforementioned 
treaties.62 The administrative work was however handed over to the World Intellectual 
Property Organisation (WIPO), a United Nations (UN) agency established in 1970.63   
The countries in the global north, during the cold war era, however faced problems of trade 
distortions in the IPRs field. They were frustrated by the fact that most developing countries 
(DCs) had failed to join WIPO and therefore had no obligation to incorporate IPRs in their 
legislation.64 In addition, they complained that WIPO was not ideal to protect their interest 
due to the lack of effective protection for IPRs in new fields, the lack of substantive standards 
and an effective enforcement mechanism.65 
To address these problems, developed countries considered a change in IPRs negotiations 
from WIPO to multilateral trade negotiation. The United States (US) and the European 
Commission (EC) responded by recommending that IPRs be made a topic under the General 
                                                          
57 Aplin T & Davies J Intellectual Property: text, cases and materials 2 ed (2013) 24. 
58 (1883) 828 UNTS 305.  
59 (1886) 1161 UNTS 3.  
60 A trademark is a symbol, word, device, name, design or combination of any of these which distinguishes the 
goods and services of the owner from others. See Bird RC & Jain SC The Global Challenge of Intellectual 
Property Rights (2008) 5. An industrial design constitutes the ornamental or aesthetic aspect of an article. See 
WIPO ‘Industrial Designs’ available at http://www.wipo.int/designs/en/ (accessed 15August 2018).  
61 A copyright is a legal right over a material which guarantees its creator to use it to the exclusion of all others. 
See Darkey EM & Akussah H ‘Academic Libraries and Copyright Issues in Ghana: University of Ghana in 
Focus’ (2009) 36 International Journal of Legal Information 434. 
62 Aplin T & Davies J (2013) 25. 
63 Aplin T & Davies J (2013) 25. 
64 Brewster R ‘The Surprising Benefits to Developing Countries of Linking International Trade and Intellectual 
Property’ (2011) 12(1) Chicago Journal of International Law 9. 
65 Brewster R (2011) 10. 
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Agreement on Tariffs and Trade (GATT) which was aimed at establishing a post-cold war 
world system for trading through rounds of negotiations.66 The GATT platform gave greater 
leverage for the US and EC to negotiate because of their large domestic markets and the 
outcome of the negotiations was preferred to WIPO’s protection due to the GATT’s ability to 
create a nexus between IPRs and other issues within the GATT, in addition to a more effective 
way of settling disputes.67 At the Uruguay round of negotiations, the WTO was established 
and the TRIPS Agreement was adopted as a multilateral agreement to deal with IPRs.68   
2.2.2 Key principles and features 
The TRIPS Agreement came into force on 1 January 1995 and it is to date known to be the 
most ‘comprehensive multilateral agreement’ on IPRs because it covers most types of IPRs 
including patents.69 It also incorporates its predecessor treaties70 and imposes an obligation 
on WTO Members (hereinafter Members) to comply with existing obligations provided under 
these predecessor treaties.71 Thus the Agreement does not operate in isolation but 
complements the existing treaties on IPRs.  
The protection of IPRs has been established with definite principles reinforced by the TRIPS 
Agreement. The main principles and features of the Agreement for the purpose of this research 
are minimum standards, rights conferred, non-discrimination principles, enforcement and 
dispute settlement. These key principles and features discussed below, are necessary for this 
research because they generally serve as a guide to Members in the application of the IPRs 
provided under the TRIPS Agreement and more importantly in the application of patents to 
help improve access to medicines.  
i. Standards 
The TRIPS Agreement sets minimum standards for IPRs protection otherwise referred to as 
the ‘substantive minima’.72 In accordance with article 1 of the Agreement, all Members are 
obliged to give effect to its provisions by enacting appropriate legislations. As such it is 
                                                          
66 Gunaratne C Genetic resources, Equity and International Law (2012) 142.  
67 Helfer LR ‘Regime Shifting: The TRIPs Agreement and New Dynamics of International Intellectual Property 
Law making’ (2004) 29 Yale Journal of International Law 21-22. 
68 Final Act embodying the results of the Uruguay round of Multilateral Trade Negotiations (1994) 33 ILM 1125.  
69 Correa CM Intellectual Property Rights, the WTO and Developing Countries: The TRIPS Agreement and 
Policy Options (2000)1.  
70 See 2.2.1 above. 
71 Article 2 TRIPS Agreement. 
72 Dinwoodie GB ‘The Architecture of the International Intellectual Property System’ (2002) 77 Chicago Kent 
law Review 994. 
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binding on Members to ensure that their legislations meet the minimum threshold required by 
the TRIPS Agreement. Thus Members have the freedom to confer protection beyond the 
minimum standard whiles respecting the principles of the Agreement. The minimum standard 
is necessary to help improve access to medicines because, it ensures certainty and 
predictability and enables Members to legislate in a broader manner and take advantage to 
access medicines without any legal ramification. 
ii. Rights conferred 
The Agreement prescribes exclusive rights which Members are obliged to confer unto 
patentees with regard to their products and processes qualifying for patent protection.73 This 
is important because an exclusive right enables pharmaceutical industries recuperate the cost 
involved in inventing, further research on the invention and to make profits. This right is 
however not absolute as it is, subject to exhaustion of IPRs.74 The exclusive right however 
cannot end before 20 years from the date of filing of the patent.75  
This conferred right is important because, it helps in determining when a patent exploitation 
to improve access to medicine can be dubbed an infringement. 
iii. Non-discrimination principles 
The TRIPS Agreement also recognises the principles of national treatment and most favoured 
nation (MFN) with some differences due to the intangible and territorial nature of IPRs.76  
The national treatment principle, imposes an obligation on each Member in protecting IPRs, 
to accord equal treatment to its nationals and nationals of other Member states subject to the 
Paris and Berne Conventions.77 This principle under article 3 of the Agreement has been 
recognised by the Appellate body in US –Section 211 Appropriation Act78 as not only a 
foundation to the development of the Paris and Berne Convention but also a keystone to the 
global trading system.79  
                                                          
73 Article 28 TRIPS Agreement. 
74 Article 6 TRIPS Agreement. 
75 Article 33 TRIPS Agreement. 
76 Van der Bossche P &Werner Z The Law and Policy of the World Trade Organization; Text, cases and 
Materials 4 ed (2017) 1003. 
77 Article 3 TRIPS Agreement. 
78 WT/DS176/AB/R (2002). 
79 WT/DS176/AB/R (2002) para 241-2. 
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The MFN principle on the other hand, require Members to extend equal advantage or favour 
granted any state ‘immediately and unconditionally’ to all Member states.80 This implies equal 
treatment ‘but to that other party which is most favoured’.81 The TRIPS Agreement was the 
first IPRs treaty to introduce this principle and its importance was emphasised by the 
Appellate body of the WTO in US –Section 211 Appropriation Act as not just new, but 
fundamental to the IPRs system.82 
The above principles give hope to especially foreign pharmaceutical companies operating in 
other Member states because, there is an assurance of fair treatment of all pharmaceutical 
companies. Guided by this principle, the fair treatment may attract more foreign 
pharmaceutical investors to support the local producers and help advance access to essential 
medicines especially for countries with little or no manufacturing capacities. 
iv. Enforcement  
The enforcement procedures under the Agreement seek to contribute to technological 
advancement and balancing rights and obligations.83 The panel report in China-Intellectual 
Property Rights84 observed that the concept of enforcement procedures used in the TRIPS 
Agreement is wide.85 This is because it contains provisions on civil and criminal procedures, 
and remedies among others, enabling right holders to effectively enforce their rights.86 The 
enforcement mechanisms ensures adherence to conditions governing the use of the WTO’s 
patent regime to access medicines and serves as a deterrent to Members. 
v.  Dispute settlement   
The seeming significance of IPRs in trade and the obscurity of balancing interests makes 
conflict over IPRs protection practically inevitable.87 The interpretation and implementation 
of the TRIPS Agreement therefore requires clear provisions on dispute resolution. As such 
the TRIPS Agreement subjects disputes to the WTO's dispute settlement procedure.88 The 
                                                          
80 Article 4 TRIPS Agreement. 
81 Jackson J The World Trading System, Law and Policy of International Economic Relations (1997) 133. 
82 WT/DS176/AB/R (2002) para 297. 
83 Article 7 TRIPS Agreement. 
84 WT/DS362/15 (2010)  
85 WT/DS362/15 (2010) para 7. 
86 Part 3 TRIPS Agreement. 
87 Taubman A ‘Rethinking TRIPS: ‘Adequate Remuneration' for Non-voluntary Patent Licensing’ (2014) 11(4) 
Journal of International Economic Law 929. 
88 India - Patent Protection for Pharmaceutical and Agricultural Chemical Products WT/DS50/AB/R (1997) para 
29. 
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procedure adopted by the Dispute Settlement Body of the WTO instils confidence in its 
Members and ensures that, the exploitation of patents without adhering to the conditions, will 
be fairly resolved by the WTO to protect both patentees and users. 
From the above, it can be observed that the TRIPS Agreement and its guiding principles shape 
the IPRs system and more importantly patents. Having discussed the historical antecedent of 
the TRIPS Agreement and it guiding principles, the next section will examine the TRIPS 
Agreement and Public health with specific reference to the relationship between access to 
medicines as a human right and IPRs.  
2.3 Intellectual property rights and Public health 
The TRIPS Agreement as indicated above does not only protect right holders but carefully 
strikes a balance between the patentees and users of the right. For the WTO’s patent system 
to be finding an optimal balance between patentees and the users with regards to public health, 
there must exist a relation between access to medicines and IPRs. Therefore the relationship 
between access to medicines and IPRs will be examined in the next section to determine IPRs’ 
impact on access to medicines. 
2.3.1 Relationship between access to medicines and intellectual property rights 
Human rights and IPRs are often considered as two distinct areas of law. The latter seeks to 
incentivise the creativeness of people and as such the right is not permanent but temporal 
which can be ‘revoked, licensed or assigned’ to another person while human rights are 
permanent and inherent and therefore ‘fundamental, inalienable and universal entitlements’ 
to individuals or groups.89  
Despite the differences in the nature, basis and operation of these two rights, the two rights 
have successfully coexisted culminating into the emergence of two approaches as to how a 
good interface can be created between them.90 The first approach sees the interface created 
by human rights and IPRs as conflicting because strong IPR protection undermines and 
impedes the enjoyment of human rights whiles the second approach sees the two rights as 
                                                          
89 UN Committee on Economic, Social and Cultural Rights (CESCR) General Comment No. 17: The Right of 
Everyone to Benefit from the Protection of the Moral and Material Interests Resulting from any Scientific, 
Literary or Artistic Production of Which He or She is the Author (12 January 2006) E/C.12/GC/17 Para 1 
available at: https://www.refworld.org/docid/441543594.html (accessed 9 July 2018). 
90 Helfer LR ‘Human rights and intellectual property: conflict or co-existence?’ (2003) 5 Minnesota Intellectual 
Property Review 47. 
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compatible as the rights encourage inventions and incentivise inventors.91 It is important to 
note that striking the balance between inventors and users has always been difficult. 
One area of connection between human rights and IPRs relates to the TRIPS Agreement.92 
Attention was given to the TRIPS Agreement by the UN Human Rights Systems which then 
adopted Resolution 2000/7 in the year 2000 when the transition period of DCs was expiring.93 
The Resolution identified the existence of ‘actual or potential conflicts’ between TRIPS and 
the realisation of human rights in a wide spectrum of factors.94 With regard to the right to 
health, this relationship is seen between patents and access to medicines, especially 
HIV/AIDS medicines which are mostly patented.95 
To address these conflicts, the Sub-Commission on Protection and Promotion of Human 
Rights of the UN which was tasked to set out a new agenda to review IPRs and to give it 
primacy delivered its task through resolutions and reports. The UN special rapporteur, argued 
that IPR protection has undermined human rights objectives and in establishing a relationship 
between the two rights under consideration, observed as follows:  
‘a product patent enables a patentee to set high prices. Higher standard of patent 
protection, which can reduce the number of easily granted patents, can facilitate 
competition and lower the prices of medicines. Lower standards of patent protection, 
however, which can increase the number of easily granted patents can lead to higher 
prices. Generic competition in the field of pharmaceuticals therefore has the potential to 
significantly lower prices and increase access.’96  
From the above, patents have direct impacts on access to medicines because they have the 
potential to improve access by providing incentives for creativity especially for novel 
diseases as well as restrict access because of  higher prices. This confirms a relationship 
between the two rights and the fact that patents are real barriers to access medicines, the 
                                                          
91 Helfer LR (2003) 48. 
92 Helfer LR (2003) 54. 
93 Reichman JH ‘The TRIPS Agreement Comes of Age: Conflict or Cooperation with the Developing 
Countries?’ (2000)32 Case Western Reserve J Int’l L 441. 
94 The Sub-Commission on the Promotion and Protection of Human Rights 52nd Session Intellectual Property 
Rights and Human Rights, Res. 2000/7 Doc. E/CN.4/Sub.2/RES/2000/7 preamble 11 available at 
http://ap.ohchr.org/documents/alldocs.aspx?doc_id=8200 (accessed 17 September) .  
95 Yamin AE ‘Not Just a Tragedy: Access to Medications as a Right under International Law’ (2003) 21(2) 
Boston University International Law Journal 325. 
96 United Nations Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest 
Attainable Standard of Physical and Mental Health (2009) UN DOC. A/HRC/11/12 para 19 available at 
https://www2.ohchr.org/english/bodies/hrcouncil/docs/11session/a.hrc.11.12_en.pdf  (accessed 17 September).   
https://etd.uwc.ac.za
19 
 
absence or relaxation, and use of such a relaxation can improve access to medicines. In 
addition, the Human Rights Council recognising the nexus between patents and access to 
medicines called on countries to utilise fully the TRIPS flexibilities as an option to improve 
access to medicines.97  
Having established the relationship between patents and access to medicines and its impact, 
with the Human Rights Council calling for the utilisation of the TRIPS flexibilities, it is 
important to know what these flexibilities within the WTO patent system are. 
2.4 Patent-related flexibilities within the Trade-Related Aspects of intellectual 
Property Rights Agreement and access to medicines 
This part discusses what the flexibilities within the TRIPS Agreement are and how they 
promote access to medicines while still respecting the rights of patentees.  
2.4.1 Meaning of flexibilities 
The flexibilities refers to the  options by which TRIPS obligations can be incorporated  into 
national laws so that WTO Members can exploit it to suit their national interest without having 
to breach the principles in the TRIPS Agreement.98  
Ghanotakis describes TRIPS patent-related flexibilities, in the context of health, as follows: 
‘WTO Member countries were giving some room to manoeuvre and customize their 
patent laws in accordance with their unique legal systems, public-health situations and 
development needs. In particular, Members were given the ability to adopt certain 
measures that neutralise the impact of exclusive rights, promote competition and facilitate 
access to medicines.  There were several “flexibilities” inherent in the TRIPS Agreement.  
All of those measures, consistent with the TRIPS Agreement, reduce prices and increase 
the affordability of medicines, without negatively affecting future R&D’.99 
From the above definition, the flexibilities are safeguards aimed at helping governments 
resolve challenges in accessing patented medicines for all diseases without any implications. 
                                                          
97 UN Human Rights Council Resolution on access to medicines in the context of the right to health UN Doc 
A/HRC/23/L.10/Rev.1 available at   
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The nature of the flexibilities are such that they must be first incorporated into the legislative 
framework of Members before they can be utilised. Thus, even though the flexibilities give 
room for countries to manoeuvre, it cannot be used to breach or neglect obligations under the 
TRIPS Agreement.  
The flexibilities identified in the TRIPS Agreement which aims at ensuring access to 
medicines are compulsory licensing and government use, parallel importation, exemption 
from patentability, patentability criteria, test data protection, transition period and competition 
laws. These flexibilities will be examined in details in subsequent sections. Before examining 
the flexibilities, their general legal basis will be discussed in the next section.     
2.4.2 Legal basis for flexibilities  
The TRIPS Agreement is the main legal instrument from which the flexibilities derive their 
legality. The Doha Declaration also supplements the TRIPS Agreement to give legality to the 
use of the flexibilities. This section therefore discusses the TRIPS Agreement and the Doha 
Declaration as the general legal basis for the flexibilities.    
a) Provisions in the TRIPS Agreement   
The term ‘flexibility’ is first used in paragraph 6 of the preamble of the TRIPS Agreement to 
recognise the different levels of development of countries and the need to allow some level 
of special and differential treatment in the form of bespoke arrangements to meet the needs 
of Members as outlined in articles 65 and 66 of the TRIPS Agreement. This flexibility can 
also be gleaned from the language of article 1(1) which sets a minimum threshold enabling 
Members to legislate in a manner that promote access to medicines without any legal 
implications. 
The flexibilities also result from the objectives and principles enumerated in article 7 of the 
TRIPS Agreement which refers respectively to IPRs being enforced in a manner that 
contributes to ‘social and economic welfare, and to a balance of rights and obligations’.100 
Article 8 of the TRIPS Agreement also encourages Members to give much attention to vital 
areas like health especially in the implementation of their laws and indirectly seems to 
reiterate the need for the domestication of the flexibilities. Thus this provisions guarantee the 
use of the flexibilities in a manner which ensures an optimal balance between right holders 
and the users. 
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b) The Doha Declaration  
In addition to the TRIPS Agreement, the Doha declaration was dictated by different 
interpretations given by developed countries and DCs to the applicability of the TRIPS 
provisions. DCs in seeking to clarify whether the TRIPS flexibilities provided sufficient 
grounds to access medicines argued that, the TRIPS Agreement permitted them to take 
measures to address their public health concerns and needs.101 In advancing their argument, 
DCs sent a strong signal to developed countries that, they will take steps to advance their 
essential needs.102 Developed Countries on the other hand argued that, the Agreement already 
strikes a balance by accommodating DCs and LDCs through the use of transition period 
flexibility which gives them time to implement the Agreement and as such the only flexibility 
they recognise.103  
As a result of these divergent views, there was a ministerial meeting in Doha, the capital of 
Qatar in 2001 which adopted the Doha Declaration.104 The Declaration affirmed that, the 
provisions in the Agreement should not prevent Members from taking measures to solve their 
public health needs.105 It urged Members to interpret the TRIPS Agreement in a manner which 
supports public health needs of countries and in particular access to medicines.106 Thus the 
Declaration basically reaffirmed the existence of numerous flexibilities and not just transition 
period as was argued by developed countries.   
Further, it recognised the needs of especially LDCs in accessing medicines and urged the 
committee to find a more sustainable solution to insufficient or no manufacturing capacity 
challenges facing Members by the end of the year 2002.107 In the year 2003, a decision was 
reached which culminated into an amendment in the year 2005 and entered into force in the 
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year 2017.108 The details of the Declaration, Decision and Amendment will be discussed in 
the flexibilities in subsequent sections. 
From the above discussions, the Declaration is a separate document which has led to several 
decisions and outcomes now incorporated into the TRIPS Agreement. It gives context to the 
interpretation of the TRIPS Agreement and according to the rules of treaty interpretation, the 
Declaration needs to be taken into account when interpreting the TRIPS Agreement.109 It can 
also be regarded as a ‘subsequent agreement’ between the parties regarding the interpretation 
of the TRIPS Agreement and the application of its provisions.110 The Declaration also 
evidences the budding stages of subsequent practice that can be used in interpreting the TRIPS 
Agreement.111 In Japan-Taxes on Alcoholic Beverage112 the Appellate body held that a 
subsequent practises between parties to a WTO treaty may have the same legal status as a 
WTO treaty.  
From the above, the Doha Declaration has been very instrumental in clarifying and 
reaffirming the obligations under the TRIPS Agreement and therefore it is right to regard it 
as a legal basis for the utilisation of flexibilities.  
2.4.3 The flexibilities promoting access to medicines 
The flexibilities create an equilibrium between the exclusive rights conferred under the TRIPS 
Agreement and the interests of the public. The flexibilities identified in the TRIPS Agreement 
promoting access to medicines and to be discussed are: 
 compulsory license and  government use 
 parallel importation 
 exemption from patentability 
 patentability criteria 
 transition periods 
 test data protection and  
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 competition laws 
These flexibilities with the exception of transition periods which has lapsed will be discussed 
in subsequent sections to understand what they mean, the conditions for their use and how 
they can be used by Members to help improve access to medicines.  
2.4.3.1 Compulsory license and government use 
A compulsory license is the authorisation by the state to a third party (generic manufacturer) 
to exploit a patented invention without permission from the patentees.113 A government use 
also referred to as ‘crown use’, is the right exercised by government itself or agents of the 
government to exploit a patent without the consent of a patentee.114 This flexibility derives its 
source from article 31 of the TRIPS Agreement.  
The provision does not expressly provide exhaustive grounds upon which a compulsory 
license may be issued and thus leave it to Members to determine their own grounds for its 
grant.115 As such, Member states authorise compulsory license mostly on grounds of public 
interest, public health and nutrition, national emergency, anti-competitive behaviours, 
dependant patents and failure to exploit.116 This provision enables countries to legislate in a 
broader manner to import, manufacture and exports medicines. 
Notwithstanding the fact that article 31of the TRIPS Agreement does not limit the grounds 
for compulsory license, its utilisation is however premised on some procedures and conditions 
summarised below.117  
1. The Agreement requires the grant of a license to be considered on its individual merits 
with express authorisation from a patentee on reasonable commercial terms.  
2. There must be an establishment of prior but futile negotiations with the patentee for a 
voluntary license.  
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3. The license granted must define the purpose and timeline for its use since it is not 
granted in perpetuity and can only be terminated if upon assessment, the condition is 
not likely to return. 
4. It must be made available for everyone with capacity to exploit, however, it must not 
be assigned by any other enterprises unless it receives a grant from the State or enjoys 
similar goodwill. 
5. It must consider the commercial interest of patentees and its use must be limited to the 
domestic market. 
6. Adequate remuneration must be paid to the patentee taking into account the economic 
value of the license. Conflicts on remuneration can be challenged in a court or 
reviewed by a higher authority. 
7. Where the license is issued for second use, the invention must involve an important 
technical advancement of considerable economic significance in relation to the 
invention claimed in the first patent. 
The conditions summarised above ensures that, inasmuch as Members are exploiting 
compulsory license to advance access to medicines, a patentee is also protected to encourage 
innovation. In the case of government use order, the above conditions apply however, prior 
negotiations are waived because the ‘government acts ex officio’ to address public health 
concerns of the country but adequate compensation must be paid.118 This waiver helps avoid 
any delay strategies and accelerates the process especially where there is an outbreak of 
diseases requiring lifesaving medicines. It also enables the government to limit remedies 
against itself in respect of remuneration.119 
Compulsory license as discussed above thus enable countries to produce generic versions of 
any drug or import them despite its procedural requirements to improve access challenges of 
medicines which otherwise would not have been available because of patents. 
Despite it being flexible, some problems arise from a provision of the TRIPS Agreement 
which requires the production of medicines under compulsory license, to be supplied only to 
the domestic market.120 This provision limits the utilisation of compulsory license to Member 
states with manufacturing capacities and deprives others having challenges from exploiting 
                                                          
118 Correa CM (2009) 21.    
119 Article 44(2) TRIPS Agreement. 
120 Article 31(f) TRIPS Agreement. 
https://etd.uwc.ac.za
25 
 
it.121 This limitation necessitated the Doha Declaration to instruct the Council of Ministers to 
find a solution to the problem and the outcome of the Council’s meeting was the August 30 
2003 Decision discussed below.122  
a.  The August 2003 Decision 
The August 30th 2003 Decision attempted to address the problem of no or insufficient 
manufacturing capacity by waiving some of the requirements for compulsory license. The 
Decision waves the ‘predominantly for the domestic market’ limitation requirement for 
exporting Members123  and the adequate remuneration requirement for importing Members.124 
Finally several importing members who are parties to a Regional Trade Agreement (RTA) 
and sharing a health problem can pool as importers.125 This decision helps especially DCs and 
LDCs to improve their access to medicine needs as they benefit from countries which produce 
in excess but hitherto could not export because of the aforementioned limitation.  
The use of the waivers were however temporal and subject to both importing and exporting 
Members putting the mechanism in place. With regards to the obligation of an importing 
Member, there must be prior notification to the TRIPS council as an eligible member (LDC 
or Member with no or insufficient manufacturing capacity).126 In addition, the notification 
must specify the names and expected quantity of the product(s) needed. Furthermore, a 
confirmation is required to establish that the product is patented in the importing Member’s 
territory which the importing Member has granted or intends to grant a compulsory license in 
accordance with article 31 of the TRIPS Agreement with an undertaking to avoid re-exporting 
imported products.127  
The exporting Member on the other hand is obliged to ensure that the country has issued a 
license in accordance with article 31 of the TRIPS Agreement indicating that, the products 
are produced under such a system and an assurance that, only the amount needed will be 
manufactured and all exported to Members who have notified the Council.128 The exporting 
Member must also ensure special packaging of the products to distinguish the products and a 
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post on the licensee’s website indicating ‘the quantities being supplied to each destination’.129 
Finally the exporting Member has an obligation to notify the TRIPS Council with the above 
information and pay adequate remuneration to the patentee.130 
The pharmaceutical industry contends that the Decision increases competition amongst 
pharmaceutical companies in the introduction and development of new patented medicines 
which will not necessary solve the problems of DCs.131 On the other hand DCs shared  interest 
in the fact that it provide other options for medicines not under the control of patentees.132 
Developed countries with concentration of big pharmaceutical industries including the US 
shared interest in the Decision based on the fact that they generate revenue from patent 
exploitation which encourages research and development (R&D).133 Be that as it may, the 
Decision was a relief of a temporal nature despite its cumbersome procedures to most 
countries. It widened the scope of compulsory license and enabled DCs to use it however, 
simplifying it for LDCs. It also reduces cost with bulk procurement by RTAs. This decision 
subsequently led to the first permanent amendment to the TRIPS Agreement in the year 2005.    
b. The December 2005 Amendment  
The Amendment134 came to force on 23 January 2017 after two thirds of Members ratified it. 
The Amended is incorporated into the TRIPS Agreement as article 31 bis. In accordance with 
WTO Jurisprudence, the Amendment will only apply to the Members which have ratified 
it.135 Members which have not ratified it, can still rely on the August 2003 Decision to import 
patented medicines until the December 2019.  
From the above, the compulsory license flexibility despite its procedural problems is an 
indispensable mechanism not only to improve access to essential medicines but to encourage 
R&D. The opportunity given to generic manufacturers ensures availability and affordability 
of essential medicines which is a necessary component of access to medicines. 
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Having examined the compulsory license flexibility, the flexibility of parallel importation will 
be examined in the next section.  
2.4.3.2 Parallel importation  
The limited resources of countries account for differentials in pricing of medicines by 
pharmaceutical companies thereby making some medicines, cheaper in some countries than 
others.136 Countries limited by resources, are hence inclined to purchasing and importing 
patented medicines from other countries at a relatively cheap price rather than buying them 
from their local markets. The act of importing and reselling a relatively cheap medicine 
legitimately put on the market by the patentee or with the consent of the patentee is known as 
parallel importation.137 Thus, parallel importation concerns the distribution process for 
medicines in the market without direct authorisation of the patentee and not the attributes of 
the medicines.138    
The TRIPS Agreement however confers a right under its article 28(1) (a) on patentees to 
prevent third parties from importing patented products without right owners consent. This 
conferred right as held in the case of Kodak SA v Jumbo-Market AG139 is not a ban on parallel 
importation but a mere right conferred on patentees to stop imports that infringe their rights. 
The TRIPS Agreement therefore imposes an obligation on states, to adopt an exhaustion 
regime as a pre requisite to import.140 Thus the conferred right is not absolute as it is limited 
by the doctrine of exhaustion upon which parallel importation is premised.  
The doctrine of exhaustion in the context of public health is to the effect that, once a patentee 
is compensated by the first sale of medicines, the patentee is not entitled to further control any 
use or resale of medicines placed on the market because the rights are exhausted by the act of 
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selling.141 Thus the ability of the patentee to exercise his rights depends largely on the 
importing country’s treatment of exhaustion of rights.142 
As such the exhaustion regime strikes and maintains a balance between free movement of 
innovative goods and remuneration for innovation.143 Article 6 of the TRIPS Agreement 
grants Members the freedom to determine their own regime, which could be national, regional 
or international subject to the non-discriminatory principles as reaffirmed in paragraph 5(d) 
of the Doha Declaration. In jurisdictions which adopt national exhaustion, the right of 
patentees are exhausted only in respect of the first sale of products put on the market in which 
the patent is protected.144 With the regional exhaustion, the patentee’s rights are not exhausted 
until the first sale of the product within a demarcated region.145 Under the international 
regime, a patentee’s rights are exhausted upon the first sale of the medicine anywhere in the 
world by or with the consent of the patent owner.146 
While some are of the view that this flexibility controls competition and the progress of R&D 
with a resultant higher price fluctuation of medicines, others believe that parallel importation 
boosts competition, improves effectiveness and benefits consumers in importing countries.147 
Members however, seem to resort to a particular exhaustion regime based on the needs of 
their country and the objective the country wants to achieve. Thus a DC which wants to obtain 
relatively cheap but quality medicines will resort to the international regime.148 Further, 
developed countries which are more interested in protecting their IPRs are more likely to 
adopt either the national or the regional exhaustion just to restrict its circulation without their 
consent. 
Despite the dissenting views, parallel importation must be utilised by Members to improve 
their essential medicines challenges because importing relatively cheap medicines from other 
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markets tends to force domestic distributors to reduce prices of medicines and also increases 
competition.149 Members especially DCs should therefore make use of the international 
regime since by its description, it provides the best option while ensuring that the right of a 
patentee is respected.  
Having examined the flexibility of parallel importation, I will proceed to examine the 
flexibility of exemption from patentability in the next section.  
2.4.3.3 Exemption from patentability 
The TRIPS Agreement allows for some limited exceptions to rights conferred on patentees. 
The scope of these exceptions are not defined but precedent on conditions which must not 
conflict with the legitimate exploitation, interest of patentee and interest of a third party.150 
These conditions are cumulative and failure to comply with any one of the three, may result 
in the article 30 exception being disallowed.151 Even though Members have considerable 
freedom to determine their own exceptions, they do not operate automatically but require 
legislating the specific exceptions before exploitation.152 The exceptions considered by most 
countries to advance access to medicines are, research exception and early working exception, 
details of which are discussed hereunder.153  
a. Research exception 
The Panel in Canada-Patent Protection of Pharmaceutical Product,154  defined this exception 
as ‘the exception under which use of the patented product for scientific experimentation, 
during the term of the patent and without consent, is not an infringement’. Thus during the 
subsistence of a patent, this exemption can be used for all experimental purposes without 
having to go through the burden of obtaining any license from the patentee. On the other hand 
it impacts negatively on innovation because innovators do not receive any compensation for 
the use of the patent for experiments.155  
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b. Early working exception 
This exception enables the use of patented medicines without the consent of a patentee in 
order to obtain a regulatory approval of a generic product and facilitate marketing of the 
generic product right after a patent protected expires.156 This practice is allowed because, once 
patents expire, they fall back into the public domain and opens up an avenue for anyone to 
exploit.157 The exception prevents delay in entry of generic medicines and also patentees 
whose patent have expired from enjoying any form of monopoly.158  
This exception otherwise known as the bolar exception originates from the case of Roche 
Products v Bolar Pharmaceuticals.159 In this case, Bolar lost against Roche for using its 
patented active ingredient to experiment. The decision of the Court, was reversed by the US 
government by the enactment of the Hatch-Waxman Act160 which permitted generic 
manufacturers to experiment with patented drugs, obtain regulatory approvals and lunch such 
medicines when the original patent expires. This act of conducting an experiment for 
regulatory approval, without stockpiling has been affirmed by the WTO Panel as consistent 
with article 30 of the TRIPS Agreement.161 
The above exceptions promote access to essential patented medicines especially in DCs where 
certain diseases are peculiar to it through the lunch of medicines that suit these conditions 
immediately the patent expires. It thus prevent delays, monopolies, unfair competition and 
promotes further R&D. The early entry therefore reduce prices of medicines and improves 
access to medicines. 
Another flexibility which is crucial to helping address access to medicine challenges is the 
patentability subject matter which is examined in the next section.  
2.4.3.4 Patentable subject matter 
The scope of patentable subject matter and the term of patent provisions in the TRIPS 
Agreement were directed towards raising the standard for countries that were deemed by DCs 
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to fall short of a ‘minimum level’.162 According to the TRIPS Agreement, patents must be 
granted to all inventions provided that they are new, they involve an inventive step, and they 
are capable of industrial application subject to some exceptions.163 A patent can thus be 
excluded in the context of public health if it is for a method of treatment being it therapeutic 
or diagnostic.164 
There is however an inherent flexibility in the footnote of article 27 of the TRIPS Agreement 
which gives Members the freedom to determine what constitutes an invention, when an 
invention is new and when an invention is capable of industrial application. Arguably, this is 
a flexible provision as there is recognition of different shared and ethical values of societies. 
However some have argued that, the lack of definition may result in the likelihood of shifting 
away from the principle of absolute originality to exploitation of existing inventions.165 Others 
argue that, the lack of a definition may lead to the possibility of Members excluding new uses 
of medicines from patentability under their national laws.166 Be that as it may, countries can 
use this flexibility to improve access to medicines by making use of the freedom granted, to 
set strict criteria for patents and exempt the grant of patents to known inventions to support 
their right to health needs. 
Guided by this inherent freedom under article 27 of the TRIPS Agreement, India has used this 
flexibility to improve access to medicines by raising the criteria to prevent patenting known 
inventions.167 This is illustrated by the case of Novartis AG v Union of India.168 The pitch of 
this case was whether the Appellant was entitled for patent protection of a compound 
‘Imatinib Mesylate’, marketed under the name ‘Glivec’ or ‘Gleevec’.169 The court ruled that 
‘Imatinib’ failed the test of invention provided for under the Patents Act because it did not 
improve therapeutic efficacy.170 This decision is of persuasive effect and as such countries 
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can rely on it to set stringent patentability criteria for pharmaceuticals in order to facilitate the 
early entry of relatively cheaper generics. 
Having discussed the flexibility of patentability subject matter above, the next section will be 
an examination of the flexibility of test data protection.  
2.4.3.5 Test data Protection 
This flexibility requires Members to protect the secret test data submitted by pharmaceutical 
companies for regulatory approval against ‘disclosure’ and ‘unfair commercial use’.171 There 
seems to be an inherent flexibility in the language of the provision because there is no 
definition of the terms used in the provision and therefore leaves it for countries to determine 
what constitutes disclosure and unfair commercial use taking into account their policy 
objectives. This inherent freedom language in article 39(3) therefore permits the authorisation 
by government of a generic product as a result of an earlier grant of regulatory approval for 
the original product without breaching the article’s prohibition on disclosing test data 
submitted by the original pharmaceutical company.172  
The flexibility enables the early entry of medicines which reduces monopoly and encourage 
competition. Some however argue that, data protection is one incentive that can be offered 
DCs to treat their conditions since the markets in developed countries alone would not always 
justify the expenses associated with research and testing.173 To facilitate access to medicines 
especially in DCs, the protection of data is necessary to incentivise the pharmaceutical 
industries especially for countries which rely heavily on imports. 
Having examined the flexibility of test data protection, I shall proceed to examine the last 
flexibility, competition laws in the next section. 
2.4.3.6 Competition laws 
The TRIPS Agreement allow Members to adopt appropriate measures to prevent or control 
anti-competitive behaviours in contractual licenses.174 Such anti-competitive behaviours 
includes but not limited to, conditions preventing challenges to the validity and coercive 
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package licensing.175 As such a Member having cause to believe that, another Member is 
engaged in an anti-competitive behaviour may enter into consultation with that Member to 
reach a mutually satisfactory agreement.176 This flexibility when used ensures price control 
and unnecessary monopolies within the pharmaceutical industry.   
2.5 Chapter conclusion 
This chapter has demonstrated that the flexibilities of compulsory licensing and government 
use, parallel importation, exemption from patentability, patentability criteria, test data 
protection and competition laws inherent in the TRIPS Agreement can be used to advance 
access to medicines. The chapter has also established that, these flexibilities contribute to 
addressing access to essential medicines challenges while ensuring that patentees are 
protected. They are important and therefore countries must take advantage by incorporating 
them in their national legislations to enable their use without any consequences. As such, the 
next chapter will focus on the legislative framework of Ghana and its incorporation of these 
flexibilities in comparison with that of South Africa to ascertain whether the extent of 
incorporation is enough to enable their utilisation to improve access to medicines. 
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CHAPTER THREE 
THE LEGAL FRAMEWORK OF GHANA AND THE EXTENT OF 
INCORPORATION OF THE TRIPS FLEXIBILITIES INTO GHANA’S 
LEGISLATIONS IN COMPARISON WITH THAT OF SOUTH AFRICA 
3.1 Introduction 
In the previous chapter, the World Trade Organisation’s (WTO’s) patent regime and the 
health related flexibilities under the Trade Related-Aspects of Intellectual Property (TRIPS) 
Agreement were examined. The chapter established that the flexibilities, if utilised can help 
improve access to medicines.  Some have however argued177 that developing countries (DCs) 
within Sub-Saharan Africa are unable to fully utilise the TRIPS flexibilities due to ‘poorly 
executed patent systems’ within these countries. The first point of call to utilising the 
flexibilities nonetheless, is the domestication of the flexibilities. 
This chapter therefore examines Ghana’s incorporation of the TRIPS flexibilities into its 
legislative framework in comparison with that of South Africa. The first part of this chapter 
focuses on Ghana’s general legal framework and its current laws which promote the TRIPS 
flexibilities. The second part examines the extent of incorporation of the flexibilities in 
identified legislations whiles comparing with South Africa’s extent of incorporation to 
determine whether conditions are ripe for their utilisation in Ghana. This is aimed at 
answering the question, ‘What are the current national legislative frameworks put in place by 
Ghana to help utilise the flexibilities and what is the extent of incorporation and utilisation of 
these flexibilities by Ghana in comparison with that of South Africa?’178 
3.2 The General Legal Framework of Ghana 
The legal history of Ghana dates back to Britain’s colonisation of Ghana and the introduction 
of the first legislation based on English law on 24 July 1974 which shaped the drafting of 
subsequent Ghanaian legislations.179 On 6 March 1957, Ghana gained independence from 
Britain and became a republic in 1960.180 After several military interventions, the Constitution 
                                                          
177 Adusei P ‘Exploiting Patent Regulatory ‘‘Flexibilities’’ to Promote Access to Antiretroviral Medicines in 
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of 1992 was adopted and has since been in force.181 Ghana has a pluralistic legal system 
because it derives its laws from sources including, the Constitution, Acts of Parliament, 
orders, rules and regulations, the customary law of Ghana, as well as the doctrines of common 
law and equity.182 The Constitution of 1992 is thus the supreme law of Ghana. 
Having discussed the history and the sources of law in Ghana, it is important to determine the 
place of international law within the legal framework of Ghana since the TRIPS Agreement 
is an international Agreement.   
3.2.1  Relationship between Domestic laws of Ghana and International Law 
Ghana as a sovereign state has the the power to do everything necessary to govern itself. As 
an autonomous state which has relations with other countries, the laws governing this 
relationship must be clearly defined. Ghana joined the WTO in the year 1995 and 
automatically became a signatory to the TRIPS Agreement.183 
In accordance with the jurisprudence of Ghana, the accession of an international agreement 
or obligation requires subsequent ratification by an Act or a simple majority vote of 
Parliament.184 Thus in terms of the relationship between domestic and international law, the 
Constitution of Ghana adopts a dualist stance to the recognition of international law. As such 
an international treaty does not have automatic and immediate effect. This position has been 
affirmed by the Supreme Court of Ghana in the case of  Republic v High Court Accra Ex 
Parte; Attorney General (Interested Parties NML Capital Ltd & the Republic of Argentina).185 
In this case, the Court held as follows: 
‘The mere fact that a treaty has been ratified by Parliament through one of the two modes 
indicated above does not, of itself, indicate that it has been incorporated into the laws of 
Ghana. A treaty may come into force and regulate the rights and obligations of the state 
on the international plane, without changing rights and obligations under municipal law. 
Where the mode of ratification is through an Act of Parliament, that Act may incorporate 
the treaty by appropriate legislations into the municipal law of Ghana’.186 
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Thus the above case affirms that, an international treaty cannot be relied upon by Ghana 
without making the international obligation a part of the domestic laws. This judgement and 
the Constitution are therefore in line with WTO jurisprudence which requires that the TRIPS 
flexibilities be first incorporated into the laws of WTO Members (hereinafter Members) 
before their utilisation.  
Prior to the judgement in Republic v High Court Accra, Ghana had shown some interest   in 
the monist system187 contrary to dualist requirement that an international treaty be 
incorporated into the domestic legal system to be enforceable in Ghana. This was 
demonstrated in the case of New Patriotic Party v. Inspector General of Police,188 where the 
High Court of Ghana held that since Ghana was a signatory to the African Charter, effect 
could be given to the obligations which the state had signed onto even though no specific 
legislation had been passed to give effect to the Charter. This judgement was handed down 
by the Court around the same period that Ghana became a member of the WTO.  
The monist system however is in conflict with the constitution of Ghana and therefore the 
decision in Republic v High Court Accra Ex Parte; Attorney General is void. This is because 
of the supremacy of the Constitution which makes any other law found to be inconsistent with 
any of its provisions to the ‘extent of the inconsistency’, null and void.189 Additionally the 
decision of the Supreme Court being, the highest Court of Ghana overrules that of the High 
Court.  
Thus from the above discussions, Ghana cannot rely on the judgement in New Patriotic Party 
v. Inspector General of Police to utilise the TRIPS flexibilities without taking steps to first 
incorporating the flexibilities into a national legislation. 
Having stated the relationship between domestic laws and international law, this research will 
now proceed to identify the specific laws in Ghana which incorporates the TRIPS flexibilities. 
This will enable a proper examination of the extent of incorporation of the flexibilities. 
 
                                                          
187 According to the monist, there is no need for incorporation of international laws into national legislation 
before they can binding because, international and municipal law are aspects of the same juridical reality. See 
Starke JG ‘Monism and Dualism in the Theory of International Law’ (1963) 17 British Year Book of 
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3.2.2  The Laws in Ghana promoting the flexibilities 
The main legislation governing patents in Ghana is the Patents Act which is complemented 
by the Patent Regulations. The other legislations promoting the flexibilities are, the Public 
Health Act, the Protection against Unfair Competition Act and the Trademarks Act. The 
details of aforementioned laws will be discussed below to determine generally how they 
promote access medicines in the era of patents. 
a. The Patent Act of Ghana190 
The protection of patents in Ghana dates back to the colonial era when its colonial masters, 
the United Kingdom (UK) decided to extend its patent system to all its colonies.191 The UK’s 
patent system was introduced into Ghana through the Patents Ordinance of 1899 which 
enabled patents to be registered under the control of a registrar.192 The ordinance was however 
repealed by Patents Registration Ordinance (Cap 179) in 1925 which made Ghana a part of 
the UK system to serve as a re-registration point.193  
Due to the tedious nature of the registration process which caused problems such as Ghana’s 
inability to grant compulsory license, Cap 179 was repealed by the Patents Registration 
(Amendment) Decree 1972 which exempted pharmaceutical products from patentability and 
granted the Ghanaian government the right to grant compulsory license.194 A new patents 
law195 was enacted in 1992 to enable local inventors directly register patents in Ghana. This 
law solved the problem of double registration as local inventors in Ghana could obtain patents 
directly or through the Patent Cooperation Treaty (PCT) under World Intellectual Property 
Organisation (WIPO) or the African Regional Intellectual Property Organisation (ARIPO).196 
                                                          
190 Patent Act 657 of 2003 (hereinafter Patent Act of 2003). 
191 Penrose E The Economics of the International Patent System (1951) 220 - 33. 
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The Patents Law of 1992 thus made all inventions which involved an inventive step patentable 
including pharmaceuticals which were hitherto exempted.197 It also widened the grounds for 
the grant of a compulsory license and made provision for parallel importation of medicines 
which was however limited to national exhaustion.198  
The 1992 Patents Act was however considered as falling below the standards of the TRIPS 
Agreement after Ghana joined the WTO. To bring Ghana into compliance with the TRIPS 
Agreement the Ghanaian government repealed the Patents Law of 1992 culminating into the 
Patents Act of 2003.199 This Act is the main legislative instrument currently governing patent 
protection in Ghana and predominantly the law which incorporates most of flexibilities such 
as compulsory license, parallel importation and other flexibilities.  
b. Patent Regulations200  
The Regulations supplement the Patent Act and addresses matters relating to the application 
of patents, the cost of patent applications, examination of patents, the maintenance of patents 
when granted and other ancillary matters relating to patents. Thus it serves generally as a 
guide to prospective patentees.    
c. Public Health Act201  
This Act aims at preventing diseases and protecting the health of both humans and animals.202 
It governs the importation, distribution, sale and advertising of medicines in Ghana. The Act 
incorporates the flexibility of parallel importation by ensuring that medicines imported into 
Ghana, are accessible and affordable through guidelines on importation, distribution and 
sales. This Act thus ensures that, quality products are imported into the country while ensuring 
that they are in accord with the TRIPS Agreement.  
d.  Protection against Unfair Competition Act 203   
This Act aims at protecting consumers from practices which seek to cause confusion, damage 
another person's goodwill, mislead the public, secret information and unfair competition.204 
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This Act seeks to prevent unfair competition and in the context of medicines, unfair 
competition among pharmaceutical companies. 
e. Trademarks Act 205 
The Trademarks Act is important in the distribution of medicines to distinguish one from the 
other on the market. This law promotes importation of generic versions of medicines which 
require special packaging, colouring and shaping of the products to distinguish the products. 
The Trademarks Act therefore comes in to facilitate these requirements.   
From the above, Ghana has promulgated adequate legislations to promote the TRIPS 
flexibilities hence the second part of this chapter will examine the extent of incorporation of 
the flexibilities discussed in chapter two in the above legislations. This will be compared with 
the extent of incorporation of the flexibilities by South Africa.  
3.3 Incorporation of flexibilities into Ghana’s legislation and usage in comparison 
with that of South Africa 
The flexibilities to be discussed are compulsory licensing and government use, parallel 
importation, exemption from patentability, patentability criteria, test data protection and 
competition laws in Ghana and South Africa.206 South Africa is selected for this comparison 
because it is a DC just like Ghana and was the first country to raise awareness about access 
to medicines issues from a DCs viewpoint and uncovered the treachery of the pharmaceutical 
industry and also a pacer of compulsory licenses and parallel imports.207 
3.3.1 Compulsory licensing and government use in Ghana and South Africa 
a. Ghana 
Compulsory license and government use are covered under section 13 the Patents Act of 
Ghana (hereinafter the Act).208 The TRIPS Agreement gives freedom to determine the 
grounds for the grant of this flexibility, therefore, the starting point for examining the Act is 
section 13(1) which allows for the grant of compulsory licensing on two main grounds: 
                                                          
205 Trade Marks Act 664 of 2000.  
206 See Section 2.4.3 above for discussion of the flexibilities.  
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i. Public interest such as national security, nutrition, health or development of other 
vital sectors of the national economy and 
ii. To remedy anti-competitive practices declared by a judicial or  administrative 
process 
Ghana obviously has taken advantage of the freedom to determine the grounds for the grant 
of compulsory license and legislated broadly in that regard, taking into account its national 
needs.209 The above provision provides Ghana with a wide range of grounds to take advantage 
of the flexibilities because public interest ground is not defined and therefore not exhaustive. 
In this regard, the Interpretation Act of Ghana210 states:  
‘in an enactment, the expression public interest includes a right or advantage which enures 
or is intended to enure for the benefit generally of the whole of the people of the 
Republic.’211  
The constitution of the Republic of Ghana212 also defines public interest as: 
‘[i]ncludes any right or advantage which enures or is intended to enure to the benefit 
generally of the whole of the people of Ghana’.213  
These two definitions are not exhaustive because the word ‘includes’ and not ‘means or 
denote or connote’ is used in the definition under both the Interpretation Act and the 
Constitution. Public interest in the context of access to medicines can thus be interpreted as, 
any act which enures to the benefit of everyone in the country to have access to medicines 
when needed.  
The flexibility is granted by the Attorney-General (AG) upon recommendation by the 
Minister of Health.214 This provision may encourage especially generic drug pharmaceutical 
companies to pursue compulsory licensing since it is not granted by the courts which are 
sometimes undesirable in terms of cost and delay in procedures.215 
The license granted by the AG must specify the scope of exploitation, the time period and the 
payment of adequate remuneration to the patentee taking into account the economic value and 
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the need to remedy anti-competitive practises if that was the ground for the grant.216 The AG 
however has a discretion to maintain the authorisation if there is evidence that such 
authorisation is necessary for exploitation after the duration stated on the license.217 The 
authorisation can only be transferred with the enterprise or business of that person.218 The Act 
does not define what ‘adequate remuneration’ is just like the TRIPS Agreement.219 The above 
conditions are in accord with the TRIPS Agreement and cannot be dispensed with if 
compulsory license must be utilised. 
The authorisation is however subject to conclusion of license contracts with the patentee.220 
Therefore the request must prove that, the patentee has received from the person seeking the 
authorisation a request for a contractual license which has been unsuccessful. The requirement 
is waived in cases of national emergency or extreme urgency and as such the AG can proceed 
to authorise and thereafter notify the patentee as soon as it can.221 This waiver helps avoid any 
delays associated with the conditions especially when there are outbreaks of diseases which 
require lifesaving medicines.  
The decision of the AG with regards to granting of a license is however not final because 
aggrieved persons on matters relating to compulsory license may appeal to the Court.222 This 
provision ensures that the AG, as a public officer, acts fairly.223 
The exploitation of the invention is however predominantly for the supply of the domestic 
market.224 This controversial requirement in the TRIPS Agreement has been resolved to some 
extent by article 31 bis of the TRIPS Agreement. In this regard, the current legislation of 
Ghana does not make provision to enable the use of article 31 bis because Ghana has not 
signed the Amendment nor notified the TRIPS Council of its intention to use it.225  
                                                          
216 Section 13(2) Patents Act of 2003. 
217 Section 3(5) and (6) Patents Act of 2003.  
218 Section 13(7) Patents Act of 2003. 
219 See Section 2.4.3.1 above. 
220 Section 11(2) Patents Act of 2003. 
221 Section 13(10) Patents Act of 2003. 
222 Section 13(13) Patents Act of 2003. 
223 Articles 23 and 296 Constitution of Ghana. 
224 Section 13(11) Patents Act of 2003. 
225WTO Council for TRIPS ‘Annual Review of the Special Compulsory Licensing System 
Report to the General council’ (25 October 2017) 3 available at  
https://docs.wto.org/dol2fe/Pages/FE_Search/ExportFile.aspx?id=239708&filename=q/IP/C/79.pdf   
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In addition, the Act provides for another form of license known as non-voluntary license 
granted by the Court on grounds of ‘non exploitation’ or ‘insufficient exploitation of 
patents’.226 The first ground is invoked if after four years of filing a patent or three years after 
a patent has been granted there are no supplies in the market on reasonable terms without any 
justification, another person may apply for a non-voluntary license in Ghana to exploit it.227 
The second ground is triggered where there are supplies in the market but such supplies are 
unable to meet the demands of the market. This therefore provides Ghana with additional 
grounds to justify the utilisation of the flexibility to advance access to medicines. The license 
granted must specify the scope of exploitation, the time period and the payment of adequate 
remuneration to the patentee.228 An obligation is therefore bestowed on the person to whom 
the license is granted to exploit it within the scope, time limit and sufficiently.229 This 
invariable will motivate patentees or workers of the patent to constantly supply the market to 
prevent their patents being exploited. 
A license may also be granted where there are interdependent patents. In this case, an owner 
of a subsequent patent may apply to the Court for a non-voluntary license for an earlier patent. 
However, the precondition is that the invention must constitute a more ‘important technical 
advance of considerable economic significance’ in relation to the invention claimed under 
earlier patent.230 If the first patentee so desires, he may also request and obtain a cross-license 
on the earlier patent.231 Unlike compulsory license under section 13, section 14 of the Act 
makes provision for exploitation of second patents. 
Based on the incorporation of compulsory license and government use flexibility into Ghana’s 
legislation, a government use order was issued for public health reasons on 26 October 2005 
after a state of emergency was declared within the national human immune deficiency 
virus/acquired immune deficiency syndrome (HIV/AIDS) program.232 The notification was 
for the importation of generic antiretroviral (ARVs) from India which were patented by 
GlaxoSmithKline (GSK). The duration of license was for 3 years without the payment of 
royalties which dropped the cost of the ARVs by almost 50 per cent and government made 
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savings and since then, no government use license has been issued. 233 This was a few months 
after the December 2005 Amendment.  
Around the same period, Danadams, a local pharmaceutical company was contracted to 
supplement the ARVS imported from India and the procurement from the company had to be 
paid for with resources from the government of Ghana.234 The ARVS were thus made 
available and affordable to people who needed them.  
From the above discussions, the current legislation partially incorporates compulsory license 
because article 31 bis has not being signed and ratified. Also, some of the conditions and 
terms such as adequate remuneration are not defined. Undoubtedly, these gaps would limit 
the full utilisation of compulsory licensing in Ghana and actual usage of the flexibility.  
b. South Africa  
South Africa’s Patents Act235 and Medicines and Related Substances Control Amendment 
(MRSCA) Act236 provides for compulsory license. Generally, South Africa grants compulsory 
license on grounds of dependent patents or where there is abuse of patent rights.  
Accordingly, compulsory license on grounds of dependant patent is granted wherein the 
working of a patent is dependent on another patent and the patentee and prospective licensee 
cannot agree on the terms of licensing.237 In the case of Atomic Energy 
Corporation of SA Ltd v The Du Pont Merck Pharmaceutical,238 it was held that, the applicant 
for a license must show that the dependent patent is valid, and that the royalty he 
suggests is reasonable. 
An abuse of power on the other hand occurs where a patent is not being worked in South 
Africa or demands are not met on reasonable commercial terms.239 In addition it occurs where 
there is refusal to grant a license which prejudices the establishment of a new industry in the 
interest of the public or where demand is met but prices charged by importers are more than 
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5 October 2018) . 
234 Osewe PL, Nkruma KY & Sackey EK Access to HIV Medicines in Africa, Trade Related Aspects of 
Intellectual Property Rights Flexibilities (2008) 40. 
235 Sections 52-59 Act 57 of 1978 As Amended (hereinafter Patent Act of 1978).   
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the prices in the country of manufacture.240 These grounds legislated by South Africa are 
elaborate as they give more room to grant licenses to ensure access to medicines. The 
definition of what constitutes an abuse will thus ensure constant supply to meet the demand 
for medicines at reasonable prices.  
Compulsory licenses are granted by the Courts however, products considered to be of vital 
importance may be put under compulsory license by an order from the Minister with equitable 
remuneration to the patentee.241 The problem with the grant by the Courts is that, it is 
susceptible to all the challenges of procedure associated with the process but one may argue 
that, this is cured with the possibility of a minister having the power to issue compulsory 
license when a product is of vital importance.   
The procedural requirements follows that of the TRIPS Agreement and as such section 56(2) 
(d) of the Patents Act provides for equitable remuneration for the patentee just like the TRIPS 
Agreement without defining what equitable remuneration is. 
In addition to incorporating compulsory license in its legislation, South Africa has ratified the 
TRIPS Amendment to allow the grant of compulsory licenses to its generic suppliers to 
manufacture for domestic use and exports.242 This is a step in the right direction because it 
narrows the gap for access to medicines challenges. 
Comparing the extent of incorporation of the two legislative frameworks, South Africa seems 
to have taken a dynamic position in ensuring that patents do not overly impede its means of 
acquiring essential medicines than Ghana. With the exception of the imprecise facet around 
the determination of compensation, its compulsory license provisions cater for any 
contingency that may act as a stumbling block in ensuring that South Africa has access to 
adequate medicine for its inhabitants as compared to Ghana.243   
Having examined the extent of incorporation of compulsory license in the legislations of 
Ghana and South Africa, I shall proceed to examine the extent of incorporation of parallel 
importation in the legislations of both countries.  
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3.3.2 Parallel importation in Ghana and South Africa 
a. Ghana 
Parallel importation is incorporated under the Patents Act (the Act),244 and the Public Health 
Act of Ghana.245 The Act, under its section 11(1) encourages the exploitation of patents whiles 
imposing an obligation on exploiters to seek the consent of the patentees. This is in accordance 
with article 28 of the TRIPS Agreement which protect patentees by conferring some rights on 
them. A reading of section 11(1) of the Act alone may seem to pose a limitation on parallel 
importation. This is however not the case because the Act incorporates article 6 of the TRIPS 
Agreement on rights of exhaustion, making parallel importation possible in Ghana.246 In this 
regard, the Act provides as follows;   
‘The rights under the patent shall not extend to acts in respect of articles which have been 
put on the market in any country by the owner of the patent or with the owner’s 
consent.’247 
The above  provision’s  use of the word ‘any ‘makes  parallel importation possible so far as  
a product which enjoys protection in Ghana  is put on a market by a patentee or by a third 
party authorised by the patentee. The provision implores the utmost flexibility which is the 
international exhaustion regime.  
In the case of Rhone-Poulence SA & anor v Ghana National trading Corporation,248 the 
Plaintiffs had a patent that covered a drug called metronidazole manufactured and sold by the 
second Plaintiff under the trade name Flagyl. The Defendant who was not a licensee of the 
patentee imported generic version of the drug for sale in Ghana. The Plaintiffs sought an 
injunction to restrain sale of the drug in Ghana. The court held that a product which is made 
in accordance with a patented process and imported for sale by a third person is an 
infringement. It further held that, the exclusive rights of the plaintiffs was violated by the 
importation of the drug into Ghana. This case was however decided at the time when Ghana 
had not adopted the international system of exhaustion. Thus, should this case be brought 
before the Ghanaian Courts today, judgement will be given in favour of the Defendants 
because of the adoption of the international exhaustion regime. 
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Another legislation incorporating this flexibility is the Public Health Act.249 Unlike the Patent 
Act, the Public Health Act specifically defines parallel importation to mean ‘importing a drug 
without authorisation of the drug registration holder from another country where it is 
legitimately placed’.250 The Public Health Act only requires that a product is legitimately 
placed without defining what legitimately placed and public interest are. This opens up for 
different interpretations as to the phrase ‘legitimately placed’ which could mean anyone other 
than the patentee or his agent.  
Ghana in accordance with the incorporation, used this flexibility in the year 2000 to import 
generic medicines from India for HIV treatment manufactured by GSK who owned the patents 
that covered ‘Lamivudine’ and ‘Zidovudine’ formulations in Ghana. In the year 1998, CIPLA 
offered zidovudine to home and foreign markets at less than half the prevailing global price. 
CIPLA’s version of the drug was priced at US$ 1.16 per tablet as against the international 
prices ranging between US$ 2.90 and US$ 5.90 per tablet. In the year 2000, CIPLA made 
shipments of a combination drug Duovir (Zidovudine plus Lamivudine) to customers in 
Ghana. GSK subsequently issued a warning to prevent the sale of Duovir in Ghana.251 This 
led to a ban and affected the Ghanaian populace since the price of brand-name drugs was 
beyond the means of most Ghanaians. This ban however was not in accordance with the 
principles of parallel importation. 
From the above, the current legislations meets the minimum standards of the TRIPS 
Agreement with the adoption of the most flexible regime and the use of this has enabled 
importation of relatively cheap medicines. Ghana has fully incorporated parallel and therefore 
eligible to utilise it to advance access to medicines in Ghana.  
b. South Africa 
South Africa’s Patent Act gives the impression of a national system of exhaustion for parallel 
importation.252 The passage of the MRSCA Act253 in 1977 clarified that, South Africa has an 
                                                          
249 Public Health Act of 2012 
250 Section 122(4) Public Health Act of 2012.  
251 CIPLA Ltd. And the Provision of Anti-AIDS Pharmaceuticals available at 
http://pconway.web.unc.edu/files/2016/01/cipla_aids.pdf (accessed 17 November 2018). 
252 Section 45 (2) of Patent Act of 1978 provides that, ‘The disposal of a patented article by or on behalf of a 
patentee or his licensee shall, subject to other patent rights, give the purchaser the right to use, offer to dispose 
of and dispose of that article’. This seems to suggest a national exhaustion regime. 
253 MSRCA Act of 1997. 
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International exhaustion regime. The MRSCA Act enables the Minister to safeguard access 
whiles ensuring that, such safeguard does not contravene with the rights of the medicines 
already marketed in the country legally.254 Thus there is some protection of commercial 
interests in the country.255  
To protect consumers and patentees with regards to parallel imported medicines, the 
Consumer Protection Act256 provides that; 
‘a person who markets any goods that bear a trade mark, but have been imported without 
the approval or license of the registered owner of that trade mark, must apply a conspicuous 
notice to those goods in the prescribed manner and form’.257 
The above section ensures that, consumers make informed choices since parallel imported 
products are not covered by any guarantee of the authorised distributor.  
Arguable and from the above,  both countries have adopted the best regime, however south 
Africa, in addition to the provisions to import relatively cheaper medicines and protect 
consumers, has the Consumer Protection Act whiles Ghana’s consumer protection regulations 
is still at the bill stage waiting to be passed into a substantive law. 
In the next section, the research will discuss the extent of incorporation of the exemption from 
patentability flexibility in both countries’ legislations.    
3.3.3 Exemption from patentability 
a. Ghana 
Under the Patent Act of Ghana (the Act), the right to exploit an invention extend to acts done 
only for ‘experimental purposes’ relating to a patent invention.258 It is however unclear 
whether the experimental purpose contemplated is in respect of the common exceptions of 
research and bolar exception when the scope has not been clearly defined. 
The Panel in Canada-Patent Protection of Pharmaceutical Product defined the research 
exception as ‘the exception under which use of the patented product for scientific 
                                                          
254 Section 15(c) MSRCA Act of 1997. 
255 CIPC Submission by South Africa (2017) available at  
http://www.wipo.int/export/sites/www/scp/en/meetings/session_27/3rdparty_comments/south_africa.pdf 
(accessed 17 November 2018). 
256 Consumer Protection Act 68 of 2008. 
257 Section 25 (2) Consumer Protection Act 68 of 2008. 
258Section 11(4) Patents Act of 2003. 
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experimentation, during the term of the patent and without consent, is not an infringement’.259 
The Act states that, acts done only for experimental purposes may be exempted. It does not 
indicate which type of experiment and the use of the word ‘only’ seems to suggest that any 
type of experiment is permitted and after the experiment the findings cannot be used for any 
other purpose. The provision seems to restrict itself in terms of the type of experiment to 
advance access to medicines. As such the closest exception that can be used is the research 
exception but not the bolar exception because of the specific requirement for naming the 
exception before it can be deemed incorporated.260 The failure to specifically name the 
exceptions undoubtedly will have a negative effect on access to medicines. 
In this regard, the Clinical Pathology Department of the Noguchi Memorial Institute for 
Medical Research conducts research that contributes to intervention strategies and safeguards 
of public health in Ghana.261 Entrance Pharmaceuticals and Research Centre also exploits 
resources to produce standardised medicines through research and development in 
collaboration with University of Ghana School to help advance studies in Pharmaceutics and 
product development.262   
b. South Africa 
This exception is provided under section 69A of its Patents Act.263 This is however limited to 
the bolar exception. This allows for introduction of generic medicines on the market by using 
the patented invention other than for the purposes of obtaining regulatory approval. Further, 
the Patents Act prohibits manufacturing and hoarding a product prior to the expiry date of the 
relevant patent with a view to lunch commercial sales immediately the patent expires.264 This 
provision thus protects patentees to enjoy the term of their exclusive rights. 
Unlike Ghana which provides for experimental purpose exception, South Africa’s Patents Act 
does not make provision for research exception. The bolar exemption thus enable generic 
manufacturers in South Africa take advantage to avoid monopoly in the system. Ghana 
unfortunately does not incorporate the bolar exception.  
                                                          
259 WT/DS114 (2000) paragraph 7.69. 
260 See Section 2.4.3.3 above. 
261Noguchi Memorial Institute for Medical Research available at 
https://www.noguchimedres.org/index.php/clinical-pathology (accessed on 18 November 2018).  
262Entrance Research Centre available at http://entrancepharmaceuticals.com/research-centre.html(accessed on 
18 November 2018). 
263 Patents Act of 1978. 
264 Section 69 A Patents Act of 1978. 
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Having examined the flexibility of exemption from patentability in both countries, the next 
section will examine the extent of incorporation of the patentability subject matter flexibility. 
3.3.4 Patentability subject matter 
a. Ghana 
The Patent Act (the Act)265 of Ghana incorporates this flexibility by adopting the wording 
used by the TRIPS Agreement. Section 3(1) of the Act stipulates that ‘an invention is 
patentable if it is new, involves an inventive step and is industrially applicable’. Section 12(1) 
of Act incorporated Article 33 of TRIPS, doubling the period of patent protection to 20 years. 
This delays the entry of generic competition, and since generic competition tends to lower 
drug prices, a reduction in overall cost-savings is likely.266 
The Act further defines the aforementioned terms unlike the TRIPS Agreement which does 
not define ‘new’ and only equate ‘inventive step’ and ‘capable of industrial application’ to 
‘non-obvious’ and ‘useful’ respectfully.267 Under the Act, an invention is new if it is not 
anticipated by a prior Act.268 The Act further elaborate on prior act as everything disclosed to 
the public, anywhere in the world  prior to the filing or, where appropriate, the priority date, 
of the application claiming the invention.269  
Aside the procedural requirements necessary for application for a patent substantive 
examinations are also required to determine whether or not they are new and involve an 
inventive step.270  
From the above if an act has been done before then it cannot be termed as new. The Act also 
defines the term inventive step and capable of industrial application which is synonymous to 
the definition provided in the TRIPS Agreement.271 
The Act under its section 2 provides an elaborate list of exemptions which includes discovery, 
scientific theory or mathematical method, rules for doing business and methods used for the 
treatment of the human body by therapy or surgery.  
                                                          
265 Patents Act of 2003. 
266 Cohen JC, Gyansa-Lutterodt M, Torpey K et al, TRIPS, the Doha Declaration and increasing access to 
medicines: policy options for Ghana (2005) in 1(17) Globalization and Health online Journal 5. 
267 Article 27 TRIPS Agreement.  
268 Section 3(2) Patents Act of 2003. 
269 Section 3(3) & 4 Patents Act of 2003. 
270 Section 9 Patents Act of Ghana. 
271 Sections 3(4) and (6) Patents Act of 2003. 
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A review of this flexibility shows that Ghana has fully incorporated this flexibility into its 
current legislation with elaborate provisions explaining all the terms. Conditions are therefore 
ripe for Ghana to fully utilise it to advance access to medicines especially that it provides 
exemption for public health matters. 
b. South Africa 
South Africa adopts the same definition under the TRIPS Agreement and thus define 
patentable inventions as ‘any new invention which involves an inventive step and which is 
capable of being used or applied in trade or industry or agriculture’.272 
With specific reference to pharmaceuticals, the Patents Act gives the impression that patenting 
of new uses of known substances may be allowed.273 The TRIPS Agreement does not 
expressly refer to the patenting of new uses of known substances. South Africa also makes 
provision for patent examinations, however the depository system for the registration of 
patents skips this substantive requirement.274  
In comparison, both countries have provisions for the utilisation of the flexibility.  
The next section will examine the flexibility of test data protection and the extent of 
incorporation by both countries. 
3.3.5 Test data protection 
a. Ghana  
This flexibility under article 39 of the TRIPS Agreement aims at effective protection of data 
against unfair competition. In this regard, Ghana’s PUC Act275 aims at preventing unfair 
competition among products and services.276 Unfair competition according to the PUC Act 
includes acts in the course of industry or commercial activity that results in a breach in a 
manner contrary to honest business practices.277  
                                                          
272 Section 25(1) Patent Act of 1978.  
273 Section 25 (9) of the Patents Act of 1978 provides that ‘the fact that the substance or composition forms part 
of the state of the art immediately before the priority date of the invention shall not prevent a patent being granted 
for the invention if the use of the substance or composition in any such method does not form part of the state 
of the art at that date.’ 
274 CIPC Submission by South Africa (2017) available at 
http://www.wipo.int/export/sites/www/scp/en/meetings/session_27/3rdparty_comments/south_africa.pdf 
(accessed 17 November 2018). 
275 PUC Act of 2000. 
276 Preamble PUC Act of 2000. 
277 Section 6 (2) (a) Unfair Competition Act of 2000. 
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The TRIPS Agreement imposes an obligation on Members to protect data against disclosure 
and against unfair commercial use when data is submitted for obtaining marketing 
approval.278  The PUC Act provides protection for undisclosed information or secret 
information which it defines as that which is not readily available in the circles, has 
commercial value and subjected to reasonable steps by the person lawfully in control of the 
secret.279 The act adopts the language of Article 39(2) in providing this protection in this 
regard.   
The PUC Act however defines ‘industrial or commercial activities’ to include the activities 
of an enterprise providing a product or service.280 Thus the protection is in relation to products 
and services contrary to the protection of data as contemplated under Article 39.3 of the 
TRIPS Agreement. As such obtaining marketing authorisation from the Food and Drugs 
Authority (FDA) does not involve provision of a product or service and the submission of 
undisclosed data to obtaining marketing authorisation, is also not contemplated by this Act 
and for that reason issues of making commercial use of the data or otherwise do not arise.281 
Considering the requirement that the flexibilities be domesticated, it can be argued that the 
provisions under article 39 has been introduced into the Ghanaian legislation to protect unfair 
competition but not to protect data as envisaged by the TRIPS Agreement.  
The obligations under TRIPS cannot therefore be enforced based on this Act and this may 
lead to relatively higher prices of medicines in the absence of product substitutes. 
b. South Africa 
There is a general protection of information submitted in respect of the regulation of 
medicines against unfair commercial use.282  In this regard, the Director General of Health 
has the discretion to disclose information in respect of medicines deemed ‘expedient and in 
the public interest’.283 There is however no specific mention of this flexibility in South African 
legislations.  
                                                          
278 Section 39(3) TRIPS Agreement. 
279 Section 5 PUC of 2000.  
280 Section 2 PUC of 2000. 
281 Kunku I The Regulation of the Distribution of Pharmaceuticals and its Impact on Access to Medicines in 
Ghana (Unpublished LLM thesis Munich Intellectual Property Law Center 2014/2015) 12-13 available at 
http://www.miplc.de/research  (accessed 5 September 2018). 
282 Section 34B MRSCA Act of 1997.  
283 Section 24B MRSCA Act of 1997. 
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In comparison, both Ghana and South Africa even though have provisions to protect unfair 
competition, the provisions do not fully support the protection of data as required by the 
TRIPS Agreement. 
Having discussed the flexibility of test data protection, the final section will discuss 
competition laws in both countries. 
3.3.6 Competition Laws in Ghana and South Africa 
a. Ghana 
Ghana currently does not have a competition law. A draft bill284 however, has been in 
existence since the year 2004 awaiting parliamentary approval to be passed. Currently, the 
only legislation which makes express reference to ‘competition’ in Ghana is the PUC Act.285 
Unfortunately, the PUC Act does not create any regulatory body or administrative process for 
the purpose of enforcement and as such aggrieved persons may seek common law remedies 
in a competent court.286 This PUC Act does not address issues of restrictive business practises, 
abuse of dominant positions and mergers which are required to check monopoly and indirectly 
reduce prices of product. The absence of such a law and a regulatory body can therefore be 
used as a leverage by big pharmaceutical industries to impede access to medicines through 
higher prices. 
b. South Africa 
South Africa has a competition law287 and a competition commission which investigates and 
prosecutes restrictive business practises, abuse of dominant positions and decide on mergers 
and acquisitions applications.288 The Commission therefore aims at achieving equity and 
efficiency in the South African economy.289 In the context of pharmaceuticals, the 
commission ensures that, there is adequate and healthy competition to regulate prices of 
medicines.  
The competition Act in its section 8 seeks to prevent excessive pricing of medicines and acts 
which prevents competitors to access an essential facility. In the case of Hazel Tau and Others 
                                                          
284 Competition and Fair Trade Practices Bill (the Competition Bill). 
285 PUC Act of 2000 
286 Section 8 Unfair Competition Act of 2000. 
287 Competition Act 89 of 1998. 
288 Section 21 Competition Act 89 of 1998. 
289 Competition Commission available at http://www.compcom.co.za/ (accessed 20 November 2018). 
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v GlaxoSmithKline and Boehringer Ingelheim,290 the Applicants, Treatment Action 
Campaign291  and other non-governmental organisations filed a complaint to the Competition 
Commission against Boehringer Ingelheim and GlaxoSmithKline, the Respondents. The 
Applicants alleged that the Respondents had charged excessive prices for ARVs which 
according to them violated section 8(a) of the Competition Act.292 In addition, the Applicants 
averred that the exorbitant prices led to deaths of people living with HIV/AIDS as people 
could not afford them.293  
The commission extended its investigations to include allegations that, the Respondent had 
further violated sections 8(b) and (c) of the Act by refusing to give competitors access to an 
essential facility. The Commission then held that, the Respondents had abused their dominant 
position by charging exorbitant prices for their drugs thereby denying other pharmaceutical 
companies the right to manufacture generic versions of their patented drugs.294 The 
Respondents subsequently agreed to allow the manufacture of generic versions of their drugs 
by selected pharmaceutical companies and export to the African sub region. In addition, the 
Respondent agreed to allow importation of the ARVS for distribution in South Africa with 
royalties not exceeding 5 per cent of the net sales of the relevant ARV’s.  
This was a ground breaking ruling for South Africa because it paved way to make generic 
drugs commercially available in South Africa.295  This ruling led to significant price decrease, 
increased competition and cumulative cost saving and lowered tender prices.296 This ruling 
supports the flexibilities of compulsory license and parallel importation to help improve 
access to medicines.    
                                                          
290 Case No 2002 Sep226. 
291 Treatment Action Campaign is a South African Non-Governmental Organisation which seeks to protect and 
advocates the s rights of persons living with HIV. 
292 Case No 2002 Sep226 para 2. 
293 Case No 2002 Sep226 para 3. 
294 Case No 2002 Sep226 para 4. 
295Avafia T Berger J & Hartzenberg T ‘The Ability of Select Sub-Saharan African Countries to utilise 
TRIPS Flexibilities and Competition Law to Ensure a Sustainable Supply of Essential Medicines: A 
study of Producing and Importing Countries’ (2006) TRALAC available at  http://www.section27.org.za/wp-
content/uploads/2010/10/Avafia-Berger-and-Hartzenberg.pdf (accessed 17 November 2018). 
296 International Working Group for Research of Competition Issues in the Pharmaceutical Market  ‘South 
Africa’s Experience in Pharmaceuticals Industry: The case of antiretroviral drugs’ available at 
https://en.fas.gov.ru/upload/other/South%20Africa%E2%80%99s%20experience%20in%20pharmaceuricals
%20industry%20(H.%20Ratshisusu).pdf  (accessed 18 November 2018). 
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3.4 Chapter conclusion 
It has been shown that the TRIPS flexibilities reduces the effect of patents thereby promoting 
access to relatively cheap medicines. It is noteworthy that the legal framework and the extent 
of incorporation of the flexibilities in Ghana and South Africa are to some extent similar with 
some difference such as no provision for bolar exception, competition laws and non-
ratification of the TRIPS Amendment on the part of Ghana. Ghana’s legislative framework 
incorporates flexibilities such as compulsory license, parallel importation and research 
exception with some lacunas in these flexibilities incorporated. South Africa as the pacers in 
access to medicines even though has not incorporated all the flexibilities, has made significant 
advancement in terms of the flexibilities incorporated such as compulsory licencing, parallel 
importation, bolar exception and a functional competition law to help improve access to 
medicines. As such, Ghana’s extent of incorporation of the flexibilities is not enough to help 
improve access to medicines. There is the need to review and fix the lacunas identified in the 
legislations if the flexibilities are to be utilised as options to accessing essential medicines. 
The next chapter will examine the challenges faced by Ghana in utilising the flexibilities apart 
from the legislative gaps identified in this chapter. 
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CHAPTER FOUR 
CHALLENGES AND REASONS IMPEDING THE INCORPORATION AND 
UTILISATION OF THE TRADE-RELATED ASPECTS OF INTELLECTUAL 
PROPERTY RIGHTS FLEXIBILITIES IN GHANA 
 
4.1 Introduction 
The preceding chapter established that, incorporating the Trade-Related Aspects of 
Intellectual Property Rights (TRIPS) Agreement flexibilities into the legislations of WTO 
Members is a prerequisite for the utilisation of the flexibilities. Some have however argued 
that, elaborate provisions in the statute books in itself does not guarantee promoting access to 
essential medicine and therefore requires addressing other non-legal issues.297  
This chapter therefore explores the challenges and reasons impeding the incorporation and 
full utilisation of TRIPS flexibilities discussed under chapters two and three above. This is 
aimed at answering the question, ‘What challenges does Ghana face in utilising the 
flexibilities incorporated in its current national legislations and what challenges does it face 
in incorporating other flexibilities provided by the TRIPS Agreement?’298  
To begin with, the next section will discuss the challenges impeding the successful utilisation 
of compulsory license and government use in Ghana.  
4.2  Challenges impeding the utilisation of compulsory  license and government use 
under article 31 of the TRIPS Agreement   in Ghana 
Compulsory license has been incorporated under sections 13 and 14 of the Patent Act of 
Ghana.299 Despite the domestication of this flexibility, the actual usage of it has been limited 
as much licenses have not being granted.300 This section identifies the challenges faced by 
Ghana in utilising compulsory license as follows: 
 Administrative and infrastructure barriers 
 Size of local pharmaceutical market 
 World Health Organisation’s prequalification requirements 
                                                          
297 Adusei P ‘Exploiting Patent Regulatory ‘‘Flexibilities’’ to Promote Access to Antiretroviral Medicines in 
Sub-Saharan Africa’ (2009) 9 University of Botswana Law Journal 22.  
298 See Section 1.3 above. 
299 See Section 3.3.1 above 
300 See Section 3.3.1 above.  
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 Viability of Ghana’s local pharmaceutical industries questionable 
 Cost of raw materials 
 Lack of a substantive definition or guidelines for adequate remuneration 
 TRIPS-plus requirements  
These aforementioned challenges discussed below are not exhaustive but generally the major 
problems affecting the utilisation of the flexibility in Ghana. 
4.2.1 Administrative and infrastructure barriers 
The effective implementation of compulsory license requires a functional system with 
adequate know-how and administrative infrastructure.301 The barriers created by the 
administrative infrastructure however hinder the effective utilisation of the compulsory 
license in Ghana.302  
Issues of patents in Ghana are handled by the patent office of the Registrar General’s 
Department. The Department started the transformation of its manual registry into a digital 
format in the 2017 to create a timely and accurate online filing system. Prior to the start of 
this transformation, the manual system of filing and registering patents created problems of 
uncertainty and delay in patent searches and the determination of patent status.303 The 
challenge of uncertainties and delays however still exist as the migration unto the digital 
system is still in process. The delays therefore serve as a disincentive to prospective patentees 
who then opt to file their patent applications and searches either through the Patent 
Cooperation Treaty (PCT) or the African Regional Intellectual Property Organisation 
(ARIPO).304 A patent search at ARIPO however has been discouraging because, the results 
sometimes fails to clarify the patent status of some products. In a response to a search to 
determine the status of some products, ARIPO used an ambiguous wording: ‘It would appear 
that those products were patented in Ghana’.305  
                                                          
301 Skees S Thi-ing up the TRIPS Agreement: Are Compulsory Licenses the Answer to Thailand’s 
AIDS Epidemic? (2007) 19 Pace International LR 271. 
302 Cohen JC, Gyansa-Lutterodt M, Torpey K et al TRIPS, the Doha Declaration and increasing access to 
medicines: policy options for Ghana’ (2005) 1:17 Globalization and Health 6 available at 
https://doi.org/10.1186/1744-8603-1-17 (accessed 28 June 18) . 
303 Registrar General Department available at http://rgd.gov.gh/ (accessed 12 November 2018). 
304 See Section 3.1.2 (a) above. 
305 Osewe PL, Nkruma KY & Sackey EK Improving Access to HIV Medicines in Africa, Trade Related Aspects 
of Intellectual Property Rights Flexibilities (2008) 24. 
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These barriers created by patent infrastructure in both national and regional systems make it 
difficult to determine the status of a patent in Ghana which is necessary for the issuance of a 
compulsory license. The challenge, delays the entry of essential generic medicines because 
generic producers will want to avoid any protracted legal battles when the status of product is 
ambiguous. 
4.2.2 Size of local pharmaceutical market 
The issue of market size has an effect on the effective utilisation of compulsory license 
because a small market size may not justify investments in manufacturing generic version of 
medicines and payment of adequate remuneration to a patentee.306 Thus, where medicines are 
manufactured with potential off takers, it has an effect on its prices as a result of passionate 
savings in cost gained by an increased level of production. Most pharmaceuticals in Ghana 
however manufacture predominantly for the domestic market.307 The result is that more 
money is spent manufacturing for the local market which is serves as a disincentive to 
pharmaceutical companies manufacturing generic medicines. 
  
4.2.3 World Health Organisation’s prequalification requirements 
The World Health Organisation (WHO) prequalification of medicines programme was 
initiated in 2001 in response to the lack of harmonised system for regulating drugs in 
developing countries (DC).308 The requirement was to ensure that, medicines procured by 
governments meet the standards of ‘quality, safety and efficacy’ of medicinal products by 
manufacturers worldwide.309 Prequalification consist of five components including 
prospective manufacturers providing comprehensive data for evaluating the purity of all 
ingredients used in manufacturing finished pharmaceutical product and results of 
bioequivalence tests.310 
                                                          
306 Stirner B & Thangaraj H ‘Learning from practice: compulsory licensing cases and access to medicines’ 2013 
Pharm. Pat. Analyst 195. 
307 Cohen JC, Gyansa-Lutterodt M & Torpey K et al (2005) 7. 
308 Ra¨go L & Santoso B ‘Drug regulation: history, present and future’ in Van Boxtel CJ, Santoso B and Edwards 
IR (eds) Drug benefits and risks: International textbook of clinical pharmacology (2008) 65–77. 
309 Worku WZ, Gordon J and, Stahl MMS et al ‘Deficiencies in generic product dossiers as submitted to the 
WHO Prequalification of Medicines Programme’ (2012) Journal of Generic Medicines 9(2) 63. 
310 WHO ‘Prequalification Fact sheet’ (2010).  
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Going through the prequalification process however requires huge finances for conducting 
tests which are prohibitive to manufacturing companies.311 The inability to pay these huge 
finances result in delays in acquiring documentations.  This leaves the government of Ghana 
with no other option than to contract pharmaceutical companies and purchase the medicines 
without the WHO prequalification. The option of government purchasing medicines without 
prequalification requirements is however unsustainable because a huge chunk of money is 
spent by the government instead of the process being donor-funded.312  
A case in point is when Danadams Pharmaceutical Company which had no WHO pre-
qualification requirements had to supply Antiretroviral (ARVs) although the company had 
modern manufacturing equipment.313 The government of Ghana contracted the company for 
a year to supplement ARVS and thus the procurement from the company had to be paid for 
with resources of the government and not with funds from the Global Fund.314   
4.2.4 Viability of domestic pharmaceutical companies 
Insufficient manufacturing capacities constrain licensing activities in Ghana thus making the 
viability of Ghana's pharmaceutical companies questionable.315 Ghana has about 38 licensed 
pharmaceutical manufacturers which are good manufacturing practices (GMP) certified.316 
Of this number, about 22 are active with 17 to18 producing throughout the entire year.317 This 
number may be enough to produce medicines if all are producing at the same time. However 
if only 17 are producing then, it goes to confirm that most of the generic manufacturers in the 
country do not either have the necessary technology or market to engage in manufacturing for 
local and external consumption. In the absence of a viable market, the option of importing 
medicines becomes economically viable. 
                                                          
311 Huang Y, Pan K, Peng D et al ‘A qualitative assessment of the challenges of WHO prequalification for anti-
malarial drugs in China’ (2018) Malaria J 17:149. 
312 Osewe PL, Nkruma KY & Sackey EK (2008) 39. 
313 Osewe PL, Nkruma KY & Sackey EK (2008) 39. 
314 Osewe PL, Nkruma KY & Sackey EK (2008). The Global Fund is a 21st-century partnership organization 
between governments, civil society, the private sector and people affected by the diseases founded in 2002 
designed to accelerate the end of AIDS, tuberculosis and malaria as epidemics. The Global Fund has been 
supporting health programs in Ghana since 2002. See The Global Fund available at 
https://www.theglobalfund.org/en/overview/ (accessed 25 October 2018). 
315 Cohen JC, Gyansa-Lutterodt M, Torpey K et al (2005) 7.  
316 The draft Ghana strategy document ‘The Future of Ghana’s Pharmaceutical Industry – Building a Centre of 
Excellence in Africa’ (2010). 
317  Cohen JC, Gyansa-Lutterodt M & Torpey K et al (2005) 7.  
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Ghana’s pharmaceutical industry is more focused on the final formulation and packaging 
stages. They source their raw materials from international suppliers with Active 
Pharmaceutical Ingredients (APIs) mostly imported from India and China.318 The inability to 
produce raw materials affects the utilisation of compulsory license because, even if a license 
is issued for production in Ghana, it will not be viable for the local pharmaceutical companies 
due to the cost of the APIs. 
4.2.5 Cost of raw materials 
Most raw materials in the form of APIs needed for manufacturing pharmaceutical products 
are imported and subject to duties, taxes and tariffs.319 The taxes on these APIs imported are 
high which serve as a disincentive to pursuing compulsory license locally. In this regard, the 
government of Ghana provides exemptions in instances of public procurement to reduce the 
cost of manufacturing.320 These exemptions includes bottles, caps, drug information leaflets 
and other inputs but does not cover all active ingredients.321 The exemptions erode the 
potential cost advantage that local manufacturing can provide. This is because, the cost of raw 
materials including APIs coupled with the tax on them despite the tax exemptions may still  
be prohibitive inhibiting the use of compulsory license locally.   
4.2.6 Lack of a substantive definition or guidelines for adequate remuneration 
The TRIPS Agreement defers what constitute adequate remuneration to the discretion of 
countries.322 Unlike Japan and Canada 323 which have strict guidelines on adequate 
remuneration, Ghana has not yet established a concrete policy for determining what an 
adequate remuneration should be. The result is that, if royalties are exorbitant, it will serve as 
a disincentive to private investors especially generic manufacturers due to the unattractive 
                                                          
318 The draft Ghana strategy document (2010). 
319 The draft Ghana strategy document (2010). 
320 The Value Added Tax (VAT) (Exemption of Active Ingredients, Selected Inputs and Selected Drugs or 
Pharmaceuticals) (Amendment) Regulations of 2017.  
321 Valued Added Tax Amendment (2017). 
322 Article 31(h) TRIPS Agreement.   
323 ‘Royalty guidelines proposed by the Japanese Patent Office (1998) and UNDP (2001) set royalties from 0 to 
6% of the price charged by the generic competitor. The 2005 Canadian royalty guidelines for the export of 
medicines to countries that lack manufacturing capacity set royalties at 0 to 4% of the generic price, depending 
upon the level of development of the importing county’. See UNDP Remuneration guidelines for non-voluntary 
use of a patent on medical technologies available at http://www.who.int/hiv/amds/WHOTCM2005.1_OMS.pdf 
(accessed 21 November 2018). 
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profits. This situation inevitably makes government investment the only safe net especially in 
times of national emergencies.324 
4.2.7 TRIPS-plus requirements 
Ghana is regarded as having a TRIPS ‘plus’ status in terms of its intellectual property rights 
(IPRs) laws.325 This is because  unlike the TRIPS flexibilities which aims at balancing the 
interest of  patentees and users, most TRIPS-plus obligations aims at protecting 
pharmaceutical companies and are less geared towards promoting public health.326 The 
TRIPS-plus obligations are normally strict obligations incorporated into Free Trade 
Agreements (FTAs).327 These FTAs set standards beyond those provided by the TRIPS 
Agreement which imposes strict obligation on countries.328 Most investment agreements 
apply to rights not covered by the TRIPS Agreement and incorporate the national treatment 
principle clause without the exceptions provided for under IPRs treaties.329 The TRIPS-plus 
provisions therefore puts countries like Ghana at risk of being unable to utilise the TRIPS 
flexibilities.330  
Ghana has a bilateral FTA with the European Union with coverage in goods.331 This FTA is 
linked to the European Partnership Agreement (EPA) with the African Caribbean Pacific 
Countries332 which Ghana is also a signatory to. All European FTA’s tend confirm their  
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adherence to the Doha Declaration in their preamble yet the substantive provisions of the 
agreements include TRIPS-plus provisions which impacts negatively on access to 
medicines.333 In addition, the Commission of the European Union uses trade policies such as 
placing countries on a trade watch list to pressure countries to refrain from making full and 
legitimate use of TRIPS flexibilities.334 Ghana and other countries therefore rather adhere to 
the strict obligations in order not to be put on such trade watch lists. 
Having identified the challenges which hinders the effective use of compulsory licenses under 
article 31 of the TRIPS flexibilities, this research proceeds to identify the possible reasons 
accounting for Ghana not signing and ratifying Article 31 bis (Amendment) of the TRIPS 
Agreement.  
4.3  Possible challenges or reasons for Ghana not signing and ratifying the TRIPS 
Amendment  
The Amendment to the TRIPS Agreement came to force on 23 January 2017 after two thirds 
of WTO Members ratified it. In accordance with WTO Jurisprudence, the Amendment will 
only apply to the countries that have ratified it.335 As indicated in chapter 2, there is still a 
leeway for countries like Ghana to rely on the August 2003 Decision to import patented 
medicines until December 2019. 
The challenges discussed below have been identified as the possible reasons accounting for 
Ghana not signing and ratifying the Amendment. 
4.3.1 Status of the country 
The uncertainty of the use of article 31 bis seems to have contributed to Ghana not signing 
the Amendment which undoubtedly will have an impact on access to medicines in Ghana. 
The use of article 31 bis of the TRIPS Agreement is limited to Least developed countries 
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(LDCs) and DCs which have demonstrated that, they have no or insufficient manufacturing 
capacities.336 It is however unclear whether a DC like Ghana with about 38 local 
pharmaceutical industries can use the amendment and if so, under what circumstances.337  
4.3.2 Manufacturing capacity of Ghana 
Ghana has limited industries which can produce APIs. With manufacturing companies such 
as Danadams, Ernest Chemist and Tobinco pharmaceutical companies, the country has been 
classified as being able to reproduce drugs as long as APIs are imported.338 To facilitate local 
production, the government of Ghana has exempted some pharmaceutical products from tax 
and tariffs. If Ghana is able to exempt taxes for importing APIs, then there will be no 
motivation for signing the Amendment or notifying the council for its use once Ghana can 
import the APIs and produce for its domestic market. 
4.3.3 Administrative complexities and ambiguities concerning remuneration 
The application for the use of compulsory license comes with its administrative complexities 
such as prior notification to the TRIPS Council and both the exporting and importing countries 
obtaining compulsory licenses.339 The Amendment also limits the exporting country's 
compulsory license to a ‘single-supply basis’, implying that the entire complex process must 
repeat for each new request.340 This administrative complexities increases transaction costs 
and possibilities for delay as every license has to go through the whole process.341  
Also the ambiguity surrounding adequate remuneration may result in ‘exporting countries 
paying prices that are either too high, thereby negating the potential gains they receive as a 
result of producing low cost medicine or too low, in which case the patentee would not receive 
adequate compensation for use of his patent’.342 These administrative complexities may make 
article 31 bis unappealing to Ghana.  
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4.3.4 Political challenges of ECOWAS and pressures from developed countries 
One of the waivers in the Amendment was to enable exports to markets of other DCs or LDC 
who are parties to an RTA sharing the health problem in question.343 The waiver may however 
pose a number of administrative and technical difficulties. This is because the ECOWAS trade 
bloc to which Ghana belongs, has sixteen countries with only five anglophone countries of 
which Ghana is one.344 These countries have different legislations and more importantly the 
procurement laws are not the same. The difference in legislation may act as a barrier to 
procuring medicines or producing to export to the countries within the region. The political 
instability of most of the countries may also affect the bulk procurement and without a 
sufficient political will, the ECOWAS will find it difficult sustaining this system for the 
benefit of its member states.345  
Also, developed countries are known for pressurising DCs to refrain from using compulsory 
licenses even as they invoke compulsory licenses on their own behalf.346 Article 31 bis 
attempted to rectify this situation by including a provision preventing Members from 
challenging any measures taken in conformity with the provisions of the TRIPS Agreement.347 
However, a persistent fear of sanctions resulting from the year 2001 Brazil litigation along 
with consternation over angering pharmaceutical companies arguably deters DCs like Ghana 
from ratifying the amendment.348 
The above discussion has established that the flexibility is saddled with challenges which 
makes it difficult to utilise especially when issued for local production. The Amendment came 
as a relief to resolve some of the challenges but came with it us own challenges. This 
challenges may be disincentives to Ghana not signing the Amendment. However, do the above 
reasons and challenges for not signing the Amendment outweigh the implications?  The next 
section discusses the implications of Ghana not signing and ratifying the Amendment. 
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4.4 Implications for Ghana not signing the Amendment 
As already indicated, there is still a leeway for Countries like Ghana to rely on the August 6 
Decision to import patented medicines up until the December 2019. This however has three 
major implications for Ghana in accessing essential medicines taking into consideration the 
WTO’s jurisprudence. 
1. The first implication is that, Ghana after December 2019 cannot rely on the August 2003 
Decision to import medicines even in situations of emergency where the manufacturing 
capacity is unable to produce. This therefore might lead to shortage of medicines in 
extreme emergencies. 
2. Secondly, the local pharmaceutical industries, if they are able to produce generic versions 
in large quantities cannot expand their market size to LDCs by producing generic versions 
of medicines for exports. In the absence of potential off takers from other countries and 
any financial injections from the government to support the high cost of production in 
Ghana, this may push some pharmaceutical industries out of the market. The consequence 
is that, access to medicines may be limited.  
3. Finally, pharmaceutical industries contribute to the economy of Ghana through the 
payment of import and export taxes. If Ghana ratifies the Amendment, it may increase 
the foreign exchange of the country through exports of medicines. Ghana however cannot 
do so after the year 2019 if the Amendment is not signed. The consequence is that 
government aside ensuring access for its citizens, losses some form of revenue from 
imports and exports. 
Based on the implications identified above, Ghana stands a better chance of signing and 
ratifying the Amendment to shield it in times of emergency when its pharmaceutical industry 
cannot support the country other than not doing so now. 
Having discussed the challenges in utilising compulsory licencing, it is important to note that 
the flexibility of parallel importation is also not without challenges. The next section will 
therefore discuss the challenges impeding the utilisation of parallel importation.   
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4.5 Challenges impeding the utilisation of parallel importation in Ghana 
Ghana has incorporated parallel importation into its current legislations and adopted the most 
flexible regime of exhaustion which enables importation of essential medicines.349  Despite 
the adoption of the most flexible regime, the following major challenges have being identified 
as impeding its effective utilisation: 
 Administrative barriers 
 Influx of counterfeit or substandard products 
 Prohibited and restricted imports 
 Pharmaceutical mark-ups 
The aforementioned challenges to be discussed hereunder if addressed will to a large extent 
incentivise pharmaceutical industries to import quality but less expensive medicines to 
improve access to essential medicines in Ghana.  
4.5.1 Administrative barriers 
In Ghana, one can only parallel import products when the requisite import permits are granted 
by the designated authorities. The import permits are however difficult to obtain in Ghana.350 
Ghana has a set of guidelines administered by the Food and Drug Authority (FDA) detailing 
the procedures and conditions to be met for the issuance of an import permit for the 
importation of products. These guidelines are intended to ensure that parallel imported 
medicines are duly approved and registered by the FDA of Ghana.351 
The procedures involved in obtaining these import permits are however cumbersome. This 
places more burden on the importers and in the event of the importers not meeting the 
requirements, the licenses are not granted. These procedures and requirements include the 
importer ensuring that, the medicine intended to be imported is registered in Ghana. In the 
absence of such registration, it is incumbent on the importer to import some samples for prior 
registration with the FDA. The importer also has the duty to notify the holder of the registered 
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license of his intention to import such products. The FDA further requires an application to 
be submitted for registration of parallel import from each individual exporting country.352  
In addition, the FDA has no discretion to waive licensing requirements for medicines 
imported into the country even in times of emergency. It can however process applications 
limited to paediatric formulation, Ministry of Health (MOH) tender purposes or certain public 
health programmes but not for private pharmaceutical industries.353 
Even though the procedures are to ensure that quality products are imported, they delay the 
grant of the import license which may serve as a disincentive to parallel import. This challenge 
undeniably limits the utilisation of the flexibility and affects access to essential medicines in 
Ghana. 
4.5.2  Influx of counterfeit medicines 
In Ghana, parallel importation has led to the increase in importation of counterfeit medicines    
sourced and imported into the country which reaches the end user before undergoing the 
stringent procedures required by the FDA.354 The counterfeit medicines are easily imported 
into the country through the loose and porous borders of Ghana.355 These medicines are often 
less expensive and more accessible than the original drugs because they do not undergo any 
examinations and no taxes are paid on them.  
Due to the less expensive nature of counterfeit medicines, people patronise them more than 
the original ones imported by licensed pharmaceutical industries. Coupled with the stringent 
procedures for importation, the influx of counterfeit medicines serves as a disincentive for 
registered pharmaceutical companies to utilise parallel importation.  
4.5.3  Prohibited and restricted imports 
The government of Ghana in 2017 banned the importation drugs deferring their production to 
local manufacturers with the aim boosting local production to encourage innovation.356 The 
ban is in relation to 49 medicines which includes aluminium hydroxide or magnesium 
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trisilicate suspension, amoxicillin capsules and suspension, aspirin or caffeine tablet, folic 
acid tablet, and cetirizine tablet.357 
The ban may encourage local pharmaceutical companies to innovate but at the same time a 
restriction on the flexibility of parallel importing these 49 banned medicines. The result is 
that, even if it is not viable for pharmaceutical companies to produce these banned medicines 
locally because the ingredients to be used are expensive, parallel importation cannot be 
resorted to.   
4.5.4 Pharmaceutical mark-ups and uncontrolled distribution system 
Ghana receives discounted medicines from generic pharmaceutical industries however, mark-
ups358 between 11 to 275 percent contrary to the approved 10 per cent margin by the Ministry 
of Health wipes out many price advantages once they get into the country.359 The weaknesses 
in drug pricing controls due to an uncontrolled distribution system and absence of an 
enforceable drug price mark-up therefore makes it possible for drugs to receive several mark-
ups to cover the tariffs and duties paid.360  
The private sector pharmaceutical distribution system in Ghana has also been described as 
chaotic because of the number of intermediaries involved in pharmaceutical distribution 
which is difficult to determine.361 This chaotic system impacts adversely on the availability, 
product security and the final price of pharmaceutical products and undermines the possibility 
of consumers to obtain medicines.362 As such the FDA has adopted guidelines for good 
distribution practices aimed at ensuring quality assurance of medicines. The FDA guidelines 
unfortunately do not regulate the activities of wholesalers and retailers leaving the distribution 
system still chaotic.363 
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Given this chaotic situation of distribution, even if medicines are imported at low prices, they 
do not translate into actual benefits for the locals.364  In the absence of a competition law 
mark-ups defeat the whole purpose of parallel importing. This is made worse as Ghana does 
not regulate the prices of medicines.365 The absence of price regulations can therefore lead to 
the formation of cartels fixing prices.  
The challenges discussed above have impacted negatively on utilising parallel importation 
and the next section will discuss the challenges impeding the utilisation of the exemption from 
patentability flexibility.   
4.6 Challenges impeding the utilisation of exemption from patentability in Ghana 
Exemption from patentability has been partially introduced into the legislation of Ghana.366 
In addition to the undefined scope in the legislation, this section identifies the following major 
challenges hindering the effective utilisation of this flexibility: 
 Extension of life of patents 
 Test data and market authorisation laws 
4.6.1 Extension of life of patents. 
In Ghana, patents are granted for a period of 20 years.367 However, a problem always arise 
where big pharmaceutical companies in their bid to maintain monopoly attempt to extend 
patent life by refusing to grant licenses to generic companies.368 The process of extending the 
life of patents is known as ‘evergreening’, which is a tactic used to apply for ‘secondary 
patents over related or derivative technologies’.369 The Patents Act of Ghana does not address 
evergreening and there has not been any decisions but generics manufacturing companies do 
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however, complain that the system works against them.370 Even though there are patentability 
requirements provided under the Patent Act of Ghana, patenting of new uses of known 
substances by adding minor changes of existing drugs still persist in Ghana. Innovator 
companies also use ‘brand migration’ as a substitute in order to extend product life cycles.371 
The result is that, the practise of extending patent life acts as a disincentive for continued 
research and development in the pharmaceutical industry because the research conducted by 
prospective manufactures may become obsolete and not serve its intended purpose.  
4.6.2 Test data and market authorisation laws 
Pharmaceutical companies rely on the use of the originators’ test data or submit data for 
market authorisation.372 This process involved in submitting data for marketing authorisation 
is time-consuming and expensive for the generic industries because it require the repetition 
of  safety and efficacy testing. The process also requires finance which may discourage 
generic manufacturers from experimenting and coming out with new drugs. 
Having discussed the challenging in utilising exception from patentability, the next section 
will be a discussion of challenges in effectively utilising patentability criteria. 
4.7  Patentability criteria 
Ghana has fully incorporated this flexibility into its patent Act.373  This section therefore 
examines the following challenges which accounts for Ghana’s inability to utilise 
patentability criteria to improve access to medicines: 
 Limited expertise in patent examinations  
 Limited capacity in patent infrastructure 
These challenges to be discuss hereunder are important because it is only when a product is 
detected as having been patented that exploitation requires conditions. Experts and 
infrastructure for testing patentability are therefore necessary to detect patented products.   
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4.7.1 Limited expertise in patent examinations  
To determine whether an application merits a patent requires expert knowledge. Many DCs 
including Ghana are yet to realise the benefits of the flexibilities and have therefore failed to 
incorporate the TRIPS flexibilities into their laws because of the limited number of legal and 
technical expertise to aid in the incorporation.374 
Thus the examination to determine inventive step, new and industrial application requires 
scientists or engineers with specific technical expertise in the area of inventive step and legal 
specialist with knowledge in patent law, regulations, novelty, inventive step, claim wording 
and this should be independent of the application.375  
The challenge however is that Ghana has inadequate technical knowhow to carry out 
examinations to determine whether products submitted meet the criteria or not.376 As such, 
patents are granted to inventions which do the meet the patentability criteria. The result is that 
pharmaceutical companies are deprived of exploiting inventions which if proper examinations 
were carried out will not merit a patent. This affects access to medicines because 
pharmaceutical manufactures have to then seek the consent of a patentee to exploit the patent.    
4.7.2 Limited capacity in patent infrastructure 
The limited capacity in infrastructure poses a challenge to the examination, granting and 
administration of patents. In reality, the limitation of infrastructure leads to the skipping of 
many   substantive examinations.377 As such, where all the procedural requirements for patent 
applications   have been met, the patent is granted without adequate examination as to whether 
there is a prior application of the same invention or whether the patent has been granted as a 
result of such an application.  
In the process, inventions that meets the criteria to be exempted from patent are skipped and 
patents therefore granted to them. Currently the patent office does not conduct substantive 
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examinations due to lack of infrastructure and capacity.378 This may make it easier to acquire 
patents but difficult to challenge because challenging it will require a thorough examination. 
The result is that most patentees will stay in business for a long period without any 
improvement to the curative aspects of medicines to help address access to medicine 
challenges. 
The final challenges to be discussed is in the next section is in relation test data protection 
flexibility. 
4.8  Test data protection 
Protection against unfair competition which goes hand in hand with test data protection has 
been introduced in the legislation of Ghana. The problem however is whether this introduction 
satisfies the requirements for protecting data as provided under the TRIPS Agreement.379 The 
following in addition to inadequate legislation has been identified as the possible reasons for 
not amending the legislations to meet the standard provided for under the TRIPS Agreement: 
 Exclusive Rights   
 Interference with compulsory licensing 
4.8.1 Exclusive rights  
Exclusive rights over test data can provide patent-like protection even where pharmaceuticals 
are not covered by patents or, do not meet the standards of patentability in a country or, 
prevent the registration of a product.380 This may serves as a disincentive to reviewing the 
Protection against Unfair competition Act but also a limitation to improving access to 
medicines especially where the local pharmaceutical industries produce medicines on a large 
scale for export.  
4.8.2 Interference with compulsory licensing 
It is posited that developing countries such as Ghana are not likely to derive any real benefit 
from data exclusivity, other than as a possible boost to investment in the local pharmaceutical 
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industry.381 As such, the introduction of data protection legislation has been identified as 
causing the delay in entry of generic medicines.382. 
The absence of the data protection law makes it possible for generics to enter the market easily 
because the requirement of clinical trials is waived if the applicant can only provide 
bioequivalence thereby reducing applicant cost and allowing for the possibility of many 
generic versions to enter the market.383 This invariably drives down the prices of medicines 
and may serve as a disincentive to Ghana making provisions to protect test data.  
4.9 Chapter conclusion 
This chapter has established that in addition to the gaps identified in the Ghanaian legislations, 
challenges such as administrative infrastructure, technical knowhow and TRIPS-plus 
obligations restrict the effective utilisation of the TRIPs flexibilities incorporated into the 
current legislations of Ghana. It has also unravelled the challenges of uncertainty, 
manufacturing capacity of Ghana and political challenges as potential reasons for Ghana not 
signing and ratifying the amendments to the TRIPS Agreement and its implications. These 
challenges identified have been established as interfering with the utilisation of the 
flexibilities to increase access to essential patented medicines needed by Ghanaians to solve 
their health related matters. The final chapter of this research recognises the need to address 
these challenges to ensure utilisation of the flexibilities to improve access to medicines and 
therefore make recommendations to that effect in the next chapter.    
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CHAPTER FIVE 
CONCLUSIONS AND RECOMMENDATIONS 
 
5.1  General Conclusions 
This research set out to answer the central question: how can Ghana effectively utilise the 
Trade-Related Aspects of Intellectual Property Rights (TRIPS) flexibilities to help improve 
access to essential medicines? The scope of the study was limited to an examination of the 
current Ghanaian legislations and the extent of incorporation of the flexibilities into the 
legislations in comparison with that of South Africa. The study also focused on the challenges 
impeding the effective utilisation of the TRIPS flexibilities in Ghana apart from the legislative 
challenges. Based on this, the study was guided by the following four pertinent sub-research 
questions to help answer the main research question:  
1.1.1 What are the flexibilities provided under the World Trade Organisation (WTO) 
patent regime which can be used to improve access to essential patented medicines?  
1.1.2 What are the current national legislative frameworks put in place by Ghana to help 
utilise the flexibilities and what is the extent of incorporation and utilisation of these 
flexibilities by Ghana in comparison with that of South Africa? 
1.1.3 What challenges does Ghana face in utilising the flexibilities incorporated in its 
current national legislations and what challenges does it face in incorporating other 
flexibilities provided by the TRIPS Agreement?  
1.1.4 What recommendations can be made to ensure that Ghana fully utilise the TRIPS 
flexibilities to improve access to medicines? 
Chapter one introduced this research and established health as a basic human right recognised 
at the national, regional and international levels, with poor access to medicines identified as 
one of the challenges facing Ghana, a country whose population suffers largely from diseases 
such as malaria, tuberculosis and HIV/AIDS. The chapter identified patents as contributing 
to access-to-medicines challenges in Ghana.384 It highlighted the fact that despite the existence 
of patents, the TRIPS Agreement provides some flexibilities for the exploitation of patents by 
Members of the WTO (hereinafter Members) so as to address their access to medicinal needs. 
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This chapter further concluded that despite the TRIPS flexibilities which are aimed at 
improving access to medicines, they are not being utilised with mortality rates on the rise.385  
Chapter two addressed the first research question: what are the flexibilities provided under 
the WTO patent regime which can be used to help improve access to essential patented 
medicines? It examined the WTO Patent regime and the historical development of intellectual 
property rights (IPRs).386 It further established a positive correlation between access to 
medicines as a public health concern and IPRs.387 The chapter further examined the 
flexibilities of compulsory licensing, parallel importation, and patentability subject matter, 
exemption from patentability, and test data protection as well as competition laws as 
promoting access to medicines.388 It concluded that the flexibilities, if well utilised, will help 
improve access to medicines with legal backing of the TRIPS Agreement and the Doha 
Declaration.389 The chapter however, highlighted the current reality that, the flexibilities are 
not self-executory and it is therefore incumbent on Members to domesticate them for effective 
utilisation.390 
Chapter three addressed the second research question: what are the current national legislative 
frameworks put in place by Ghana to help utilise the flexibilities and what is the extent of 
incorporation and utilisation of these flexibilities in comparison with that of South Africa?  
The chapter examined the current legislations of Ghana which seek to incorporate the TRIPS 
flexibilities (the Patent Act, Patent Regulations, the Public Health Act, the Protection against 
Unfair competition Act and the Trademarks Act) to improve access to medicines in 
comparison with that of South Africa.391 It established that, while the current legislations of 
Ghana have been reviewed and amended to take into consideration the TRIPS flexibilities, 
their effectiveness is limited because of numerous inherent gaps. These gaps include the 
failure of Ghana to fully incorporate the TRIPS flexibilities identified in chapter two. A major 
loophole identified by the chapter is the failure of Ghana to sign and ratify the TRIPS 
Amendment or notify the TRIPS Council to use it, inadequate legislations on exception to 
patents and test data laws not meeting the requirements of the TRIPS Agreements.392 The 
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chapter established that the extent of incorporation of the flexibilities, compared to that of 
South Africa, is insufficient to fully take advantage of the TRIPS flexibilities. It was also 
established that there has been actual usage of the flexibilities, which has improved access to 
medicines and reduced cost.393 
Chapter four addressed the third research question: what challenges does Ghana face in 
utilising the flexibilities incorporated into its current national legislations and what challenges 
does it face in incorporating other flexibilities provided by the TRIPS Agreement? It 
established that, even in the situation where the statute books are filled with provisions 
incorporating the TRIPS flexibilities, their utilisation is still limited by other challenges which 
impede their full incorporation and effective use.394 Chapter four’s analysis identified 
challenges such  as technical knowhow, administrative and infrastructure barriers, the size of 
the pharmaceutical market, World Health Organisation (WHO)  prequalification 
requirements, the questionable viability of Ghana’s local pharmaceutical industry, the cost of 
raw materials, TRIPS-plus requirements, and pharmaceutical mark-ups, among others as 
impeding the utilisation of the flexibilities.395 The chapter also identified the status of Ghana, 
administrative barriers, political barriers, manufacturing capacity, and political pressures as 
possible reasons or challenges accounting for Ghana not signing and ratifying the TRIPS 
Amendment. It argued that the failure to sign the Amendment will prevent Ghana from 
importing or exporting medicines produced under compulsory licenses in times of emergency 
and reduce its foreign exchange.396 It concluded that, should these challenges be resolved, it 
will not totally erase the access to medicine challenges of Ghana but will alleviate the 
situation. 
This chapter builds on the previous chapters and advances recommendations for an effective 
utilisation of the TRIPS flexibilities to help improve access to essential medicines in Ghana.  
5.2 Recommendations 
Having identified the above issues, it is incumbent on this research to make recommendations 
on how Ghana can fully utilise the TRIPS flexibilities. It is important to note that ‘utilisation’ 
in the context of this research, implies the full incorporation and actual use of the flexibilities 
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to advance access to medicines. These recommendations flow from the key findings in the 
preceding chapters.  
5.2.1 Amend current legislations to incorporate flexibilities to the full.  
Having established that the flexibilities cannot be self-executed, this mini-thesis recommends 
that Ghana reviews and amends its current legislations to fully incorporate all the flexibilities 
discussed in the previous chapters. As such the following are specifically recommended: 
 Section 11(4) of the Patent Act of 2003 which deals with the flexibility of exemption 
from patentability should be amended by deleting the word ‘only’ from section 11(4) 
of the Patent Act. This is because it seems to suggest that, apart from experimenting 
with the patent, the experiment cannot be used for any other purpose.397 Further, the 
Act must incorporate the bolar exception flexibility in clear and unequivocal terms by 
amending section 11(4) of the Patent Act to enable generic versions of medicines to 
enter the market immediately the patent term for medicines expires to avoid monopoly 
and evergreening. Though some countries like Japan398 interpret the experimental 
purpose in their legislation to include early entry, it will be in the interest of Ghana to 
clearly incorporate the bolar exception flexibility and use it as a sword rather than 
employ the Japanese approach as a shield. The provision hereunder is therefore 
recommended: 
The rights under the patent shall not extend to acts done for scientific 
research or for the purpose of educating, testing, obtaining regulatory 
authorisations and/or registration for the purpose of commercialising the 
product after the cessation of the patent term. 
 It is further recommended that Ghana amends its Protection against Unfair 
Competition (PUC) Act in order to better prevent unfair competition; the PUC Act 
additionally ought to incorporate a provision for the protection of test data.399 A 
provision in this regard is necessary considering the fact that such provisions will 
protect the data of inventors when the country exports its pharmaceutical products. 
The provision for test data protection is also necessary considering the fact that Ghana 
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does not only produce medicines but imports to supplement its medicinal needs. On 
this point, the provision hereunder is recommended: 
1. Where data is submitted for marketing approval and the origination of 
such data involves a considerable effort, such data shall be protected 
against unfair commercial use.  
2. The data submitted shall, subject to section 1, be disclosed by the 
Minister of Health where such data is deemed expedient and in the 
public interest. 
 Finally, it is recommended that Ghana adopts a comprehensive and holistic approach 
concerning the criteria for patentability by defining all terms without leaving any 
considerable policy space to patent offices or any adjudicatory body to interpret and 
apply the criteria at their discretion.  
5.2.2 Implementation of further guidelines to facilitate the utilisation of the flexibilities 
Ghana should provide effective guidelines and regulations for patent exploiters. The 
following are specifically recommended: 
 The Food and Drugs Authority (FDA) must provide an effective regulation which 
imposes an obligation on applicants seeking market authorisation to constantly supply 
their products to the market, when their applications are granted for use after patent 
expiration. This will motivate generic companies to experiment with the patented 
medicines while patents are in force and even go further by adding to them in order to 
cure existing and emerging diseases once the market is available. This will erase any 
delays and encourage innovation to improve access to medicines. 
 The FDA must organise seminars for prospective importers to simplify guidelines on 
importation. This would make it easier to get permits for parallel imports for instance, 
thereby cutting off all the delays associated with bureaucracy by preparing in advance 
the documentations that will be needed by the FDA.400 
 Additionally, there is a need for a public health law or further guidelines to waive, 
minimise or expedite procedural and administrative requirements for medicines that 
are imported in response to a public emergency.401 The expedited process extended to 
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Ministry of Health for public procurement must also be extended to the private 
pharmaceutical companies considering the fact that the private sector responds more 
quickly to issues than the public sector, in the absence of any bureaucracies. 
 This research further recommends that, guidelines be provided for flexibilities which 
require the payment of adequate compensation to patentees.402 The guidelines should 
outline the requirement for determining the compensation and must be reasonable and 
not frustrate the purpose of ensuring access to medicines at the lowest possible price. 
For this reason royalty rates can be set at 1 to 5 per cent of the price of a generic 
product which can be increased or decreased by as much 2 per cent.  
5.2.3 Sign and ratify Article 31 bis of the TRIPS Agreement or submit intention to use 
it. 
Ghana may deem itself as not eligible to use article 31 bis because it has some manufacturing 
capacity.403 The following are however recommended: 
 Ghana must ratify the TRIPS Amendment so that in cases of emergency where its 
local pharmaceutical companies cannot produce or support the demand for essential 
medicines, it can issue compulsory licenses to foreign companies to produce for the 
country. This will also enable it import essential medicines as it did in the year 2005 
when a compulsory license was issued under the August Decision for the importation 
of Generic ARVs from India when a state of emergency was declared.404 
 Ghana must review its procurement laws to make it consistent with the procurement 
laws of ECOWAS and other Member states. This will ensure easy procurement when 
resources are pooled together to import medicines at a relatively cheaper price.405  
 The cumbersome procedures and challenges involved in invoking the Amendment 
may be resolved by the involvement of all the members of ECOWAS and not just a 
burden for Ghana alone. There should be division of labour among all members of the 
ECOWAS so as to lighten the burden of a single country like Ghana in terms of going 
through the cumbersome procedures alone.  
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5.2.4 Pass a functional  competition law which will  extend to  IPRs 
Competition laws in the instance of improving access to medicines, will force pharmaceutical 
companies to keep prices down, be innovative and ensure that consumers benefit from cheap 
but high quality products. The following are therefore specifically recommended; 
 Ghana should review and pass its draft Competition Bill into a substantive law to help 
address matters of competition and price regulation. The PUC Act is not enough to 
address such matters needed to help improve access to medicines.406 
 Furthermore, the Bill to be passed must be reviewed to fairly incorporate and elaborate 
more on intellectual property, with measures which will serve as deterrents to abuse 
of  patent rights. A lesson could be drawn from South Africa’s inclusion of competition 
law as a TRIPS flexibility to facilitate access to medicine. As demonstrated by the 
case of Hazel Tau and Others v GlaxoSmithKline and Boehringer Ingelheim407 section 
8(a) (b) and (c) of its competition Act has positively advanced access to medicine. A 
functional competition law can serve as the best ombudsman against monopoly, abuse 
of patent rights and excessive prices.  
 A competition commission must be established to administer the competition law with 
the functions of investigating and prosecuting restrictive business practises, abuse of 
dominant positions and deciding on mergers and acquisition applications. This will 
ensure adequate and healthy competition to regulate pharmaceutical products.  
5.2.5 Pass a concrete consumer protection law and protect the borders 
The government of Ghana must pass a concrete consumer protection law to protect the 
consumer. Additionally, it must man the country’s borders to prevent the influx of counterfeit 
products. The following are recommended in line with this suggestion: 
 A concrete consumer protection law must include the introduction of greater 
transparency and awareness about pharmaceutical products, promotion of competition 
in the pharmaceutical industries, education of users of pharmaceutical products and 
eradication of unfair practices. This will circumvent any consequences medicines may 
have on consumers. The protection provided in the Public Health Act can alternatively 
be amended to include the provision below: 
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A person who offers or agrees to supply, or supplies, any goods that 
have been re-formed or re-modelled must bear the original producer’s 
trademark and a conspicuous notice stating they have been reformed 
or remodelled. 
 All ports of entry must be equipped with the necessary equipment to test and detect 
counterfeit and substandard medicines.408 If such medicines are detected, they should 
be prevented from entering the market to compete with imported medicines by 
destroying them. 
5.2.6 Regulate the distribution and pricing of medicines. 
The chaotic nature of the distribution system and the pricing makes medicines inaccessible. 
The following are therefore recommended: 
 The government must partner with pharmaceuticals industries in the private sector to 
ensure the distribution of pharmaceuticals to patients at reasonable prices which may 
reduce the formation of cartels and the hoarding of pharmaceutical products by the big 
pharmaceutical companies. As such, the functions of wholesalers, distributors and 
retailers should be clearly delineated with licenses issued for particular purposes. A 
combination of any of these licenses leads to the formation of cartels and mark-ups. 
 In addition to this, the guidelines for price mark-ups must be enforced with fines for 
pharmaceutical companies which do not adhere to the guidelines. This may serve a 
deterrent to other pharmaceutical companies engaging in mark-up activities. 
5.2.7 Provide technical assistance for World Health Organisation prequalification 
requirements. 
Ghana must strengthen its partnership with the WTO, the WHO and the Global Fund in order 
for them to support it by providing simple guidelines and technical assistance to local 
pharmaceutical manufacturing companies on the requirements for WHO prequalification. The 
assistance will avoid delays associated with the application process and enable manufacturing 
companies to be contracted to produce generic versions of medicines to help improve access 
to the said medicines. The assistance will also ensure that government gets the necessary aid 
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from donor funders to pay for these pharmaceuticals and not rely on its tight budget as was 
done in the case of Danadams.409  
5.2.8 Strengthen local pharmaceutical  manufacturing companies 
A strengthened pharmaceutical industry in Ghana will contribute to improved access to 
essential and new medicines. As a result of this observation, the following are specifically 
recommended: 
 The government of Ghana must partner with pharmaceutical companies to ensure they 
meet the good manufacturing practices expected by Ghana and the world as a whole. 
The government can do this through equitable partnerships where it will inject some 
amount of money into these companies to enable them purchase the necessary 
equipment and active ingredients needed in the production of essential medicines. This 
will encourage local production of essential medicines and reduce the cost associated 
with the importation of medicines.   
 It is further recommended that, inasmuch as Ghana has a duty to strengthen its local 
pharmaceutical industry, local pharmaceutical companies on the other hand should 
strategically partner with big pharmaceutical companies in the industrialised world to 
facilitate technology transfers in order to enhance local production. The government 
of Ghana must however, support this initiative by ensuring that there are no barriers 
created to impede these strategic partnerships.  
 The government must establish a one-stop-special-purpose zone by delineating a 
geographical area close to any port of entry specifically for pharmaceuticals. Such 
delineated one-stop area should make provisions for the operator, the regulators and 
service providers within one space. This will prevent any delays because these 
regulatory authorities will only be dealing with the pharmaceutical companies within 
the enclave and this will facilitate the exportation to other countries. The tax breaks 
that will be enjoyed by virtue of being a free zone will be a motivation for 
pharmaceutical companies to move to the enclave and produce medicines to improve 
access. This can also attract foreign pharmaceutical companies to partner with local 
ones to improve access to medicines. 
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5.2.9 Build patent infrastructure and technical knowhow 
In order to build an effective patent infrastructure and technical knowhow, the following are 
specifically recommended: 
 The Registrar General’s department should be well equipped with the necessary patent 
infrastructure needed for patent examinations as well as patent searches. This 
infrastructure should be manned by experts and other technical staff who could also 
be trained on the job. The expertise should comprise of Ghana’s research institutions 
and universities such as the Noguchi Centre for Medical Research. Technical 
assistance could also be sought from the World Intellectual Property Organisation 
(WIPO) and other WTO members in that specific regard. The availability of experts 
and infrastructure will reduce delays. 
 To facilitate applications, matters involving documentations must be migrated to the 
paperless system and accessible in any part of the world without prospective patentees 
or exploiters coming to Ghana to ascertain such information.410 On the other hand all 
substantive examinations, especially to identify whether or not an invention meets the 
patentability criteria, should be carried out in Ghana or any designated country once 
the infrastructure is available and decentralised to avoid any delays just at one 
registry.411 Thus Ghana can at least have a registry for its southern sector as well as 
one for its northern sector with 5 regions in each sector. 
 The databases of the registries must be regularly updated with current data to ensure 
that searches for patents are not delayed.412 Ghana, as a member of the Africa Regional 
Intellectual Property Organisation (ARIPO) should let its voice be heard at meetings 
of this body on matters concerning patent applications by recommending that it 
establishes a reliable database to facilitate the search for patent status to strengthen 
information flow and facilitate the utilisation of the TRIPS flexibilities. 
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5.2.10 Avoid TRIPS-plus Agreements 
It is recommended that Ghana carefully assesses the implications of signing any agreement 
which imposes higher burdens than that expected from the TRIPS Agreement before signing 
such agreements.413 Ghana must refrain from signing agreements which appear to discourage 
the use of the flexibilities as a means of attracting foreign investment and ignore any trade 
sanctions used as a means of circumventing the use of the flexibilities.  
5.3   Conclusion 
From the findings of this research, it is clear that incorporating TRIPS flexibilities into 
national legislations does not automatically yield better access to medicine. One thing which 
is certain however is that, the first step to utilising the flexibility either for local production or 
importation of medicines is incorporating them into national legislations to avoid any 
protracted legal battles. While it is acknowledged that fully incorporating the flexibilities into 
national legislations will have its own challenges, it is without a shadow of doubt that it is the 
most appropriate course to follow if the flexibilities are to be fully and effectively utilised. As 
already discussed, there is the need to further provide guidelines in support of the flexibilities 
once they are fully incorporated. There is no doubt that having clear and unambiguous 
guidelines will greatly enhance efforts to avert all incidences of misinterpretation and delays 
associated with granting of licenses to use the flexibilities. It is clear, from the findings of this 
study that despite having incorporated these flexibilities, Ghana has up to now been unable to 
fully utilise them. This has mostly been attributed to other challenges beyond the law. Ghana 
therefore can effectively utilise the flexibilities to improve access to essential medicines in 
the country if the recommendations suggested above are implemented.  
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